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1 A. Summary 
 
A hallmark feature of human cancer is aberrant signaling from activated receptor 
tyrosine kinases (RTKs). Their localization in the cellular membrane allows them to translate 
environmental cues into intracellular signals, making them crucial components of signaling 
networks. Genetic alterations leading to over-expression or ligand-independent stimulation of 
RTKs are frequently observed in tumor cells and lead to deviant pathway activation. Targeted 
inhibition of tyrosine kinases with pharmacological inhibitors has had limited effects and few 
compounds have proven beneficial for large patient groups. Considering that tumors often 
express a number of different RTKs, an alternative approach would be to target downstream 
signaling pathways that are common to a variety of growth factor receptors. The 
phosphatidylinositol 3-kinase (PI3K)/protein kinase B (PKB, hereinafter Akt) pathway 
represents such a pathway. In view of the fact that this cascade is subject to numerous genetic 
alterations in human cancer, it provides a variety of potential therapeutic targets. The studies 
presented in this thesis were aimed at gaining a better understanding of the involvement of the 
PI3K family in different human cancers. This family of proteins consists of eight isoforms, 
which are grouped into three classes based on sequence homology and substrate specificity. 
While the catalytic class IA member p110α has been the focus of much attention, the role of 
the other isoforms is less clear. Therefore, we aimed to evaluate the contribution of various 
PI3K family members to cellular responses in human cancer models. 
The main aim of this study was to assess the role of individual PI3K isoforms in the 
biology of neuroblastoma (NB), a pediatric cancer that arises from neural crest cells. 
According to the NCI, NB accounts for 7-10% of all cancers diagnosed in children younger 
than 15 years of age. The enigmatic clinical behavior of this cancer ranges from spontaneous 
regression to rapid tumor progression, ultimately leading to death. Although a recent study 
reported a correlation between activation of the downstream signaling mediator Akt and poor 
prognosis, little is known about the involvement of this pathway in neuroblastoma. Therefore, 
we analyzed cell lines and patient samples for PI3K expression both at the mRNA and protein 
level. The class IA isoform p110δ was found to be over-expressed both at the mRNA and 
protein level in a subset of primary NB tumors and cell lines. Interestingly, increased 
expression of p85α/p110δ was mainly detected in children under the age of one and was 
found to inversely correlate with MYCN amplification. Based on the observation that p110δ 
was highly over-expressed in primary tumors, cell lines were generated in which p110α or 
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p110δ were stably downregulated using RNAi. Cellular responses, such as basal proliferation 
and pathway activation upon growth factor stimulation were then compared between cells 
expressing decreased levels of p110α or p110δ and control cells. We could show that cells 
with high levels of p110δ, such as SH-SY5Y, greatly depend on this isoform for survival 
under limiting culture conditions and for the proliferative response to growth factors. These 
studies unveiled a novel role for p110δ in the regulation of NB proliferation and demonstrated 
that p110α and p110δ have non-redundant functions in these tumor cells.  
  Another project was aimed at investigating the effects of specifically inhibiting PI3K 
isoforms in glioblastoma (GB). These brain tumors have a highly invasive phenotype and are 
considered the most malignant type of glioma. Although a vast number of studies have 
provided evidence that the PI3K/Akt pathway plays a crucial role in the pathogenesis of brain 
tumors, the contribution of individual PI3K family members remains unclear. Our initial 
findings have highlighted unique contributions of individual isoforms to a variety of 
biological responses. Blocking the class II isoform PI3KC2β with a selective pharmacological 
inhibitor was found to inhibit the proliferation of GB cell lines and ex vivo cultures. 
Furthermore, co-treatment with the inhibitor sensitized cells to chemotherapeutic agents, such 
as doxorubicin. Preliminary results with inhibitors of the class IA PI3Ks showed that 
inhibition of p110α attenuates activation of Akt and S6 kinase (S6K) in response to growth 
factor stimulation and affects anchorage-independent growth. The related isoform p110β also 
appears to contribute to anchorage-independent growth and cellular motility. The exact 
mechanisms underlying these differences are not yet understood. 
Taken together, this dissertation explores the role of PI3K signaling in NB and GB. It 
highlights the functional differences of individual catalytic PI3K isoforms, thus confirming 
the idea that the members of this family of proteins can have specific and non-overlapping 
functions in cellular responses. The involvement of PI3K/Akt signaling in human 
malignancies has sparked interest in targeting PI3Ks as a novel therapeutic approach. 
However, the existence of eight isoforms necessitates a detailed understanding of the 
individual functions, thus delaying clinical application of isoform-specific PI3K inhibitors. 
Nevertheless, the wait could well pay off, considering that these proteins are expressed in a 
tissue-specific manner and seem to have non-redundant functions, thus making them very 
attractive molecular targets. 
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1 B. Zusammenfassung 
 
Ein bezeichnendes Merkmal, welches bei Krebserkrankungen häufig beobachtet wird, 
ist die abnormale Aktivierung von Rezeptor-Tyrosinkinasen (RTK). Ihre Lokalisierung 
innerhalb der Zellmembran erlaubt es diesen Proteinen, Signale aus der Umgebung in 
intrazellulläre Antworten zu übersetzen, was sie folglich zu wichtigen Bestandteilen von 
Signal-Netzwerken macht. Genetische Veränderungen, welche zu Überexpression oder 
Ligand-unabhängiger Stimulierung von RTK führen, haben oftmals eine Überaktiverung von 
Signalkaskaden zur Folge. Gezielte Blockierung von Tyrosinkinasen mit pharmakologischen 
Inhibitoren als Krebstherapie hat bisher unbefriedigende Resultate ergeben, und nur wenige 
dieser Verbindungen haben sich für grosse Patientengruppen bewährt. In Anbetracht der 
Tatsache, dass Tumoren oftmals eine Vielzahl verschiedener RTK exprimieren, wäre ein 
alternativer Ansatz, Signalkaskaden, welche meheren RTK gemeinsam sind, ins Visier zu 
nehmen. Der Phosphatidylinositol 3-Kinase (PI3K)/Protein Kinase B (PKB, nachfolgend Akt) 
Signalweg stellt eine solche Kaskade dar. Da Proteine dieses Signalwegs oft von genetischen 
Veränderungen betroffen sind, bieten sich eine Vielzahl von interessanten Zielmolekülen an. 
Die vorliegende Arbeit sollte dazu beitragen, ein besseres Verständnis der Rolle der einzelnen 
PI3K in verschiedenen Krebsarten zu erlangen. Diese Proteinfamilie besteht aus acht 
Mitgliedern, welche je nach Vorkommen im Gewebe sowie Substratspezifität in drei Klassen 
unterteilt werden. Obschon der katalytischen Klasse IA Isoform p110α viel Beachtung 
geschenkt wurde, bleibt die Rolle der anderen Mitglieder noch unklar. Unser Ziel war es 
daher, den Beitrag einzelner PI3K Isoformen an verschiedene zelluläre Vorgänge in 
menschlichen Krebszellen zu erörtern. 
 Das Hauptziel dieser Studie lag darin, die Rolle einzelner PI3K in der Biologie von 
Neuroblastoma (NB), einer pädiatrischen Krebsart, welche aus Zellen der Neuralleiste 
entsteht, zu ermitteln. Gemäss dem National Cancer Institute macht NB 7-10% aller 
Krebsdiagnosen in Kindern unter 15 Jahren aus. Das rätselhafte klinische Verhalten dieser 
Krebsart reicht von spontaner Regression zu schnellem Tumorwachstum, welches 
schlussendlich zum Tod führen kann. Obwohl eine kürzlich veröffentlichte Studie eine 
Korrelation zwischen Aktivierung von Akt, welches ein wichtiges Mitglied des PI3K 
Signalwegs darstellt, und schlechter Prognose aufzeigen konnte, bleibt die Rolle dieser 
Signalkaskade in NB noch unbekannt. Wir haben daher die Expression von PI3K in primären 
NB Tumoren und Zelllinien untersucht, sowohl auf der mRNA- wie auch auf der 
Proteinebene. Unsere Untersuchungen haben gezeigt, dass die Klasse IA Isoform p110δ 
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sowohl auf der mRNA- wie auf der Proteinebene in einer Teilgruppe der Patienten 
überexprimiert ist. Interessanterweise wurde die Überexpression von p85α/p110δ vor allem 
bei Kindern, die zum Zeitpunkt der Diagnose noch nicht einjährig waren, nachgewiesen. Des 
weiteren konnten wir zeigen, dass zwischen der Expression von p110δ und MYCN-
Amplifizerung eine negative Korrelation besteht. Aufgrund der Beobachtung, dass p110δ in 
primären Tumoren stark überexprimiert ist, wurden Zelllinien generiert, in welchen p110α 
oder p110δ stabil herunterreguliert war. Zelluläre Antworten wie Proliferation oder 
Aktivierung von Signalkaskaden nach Stimulierung mit Wachstumsfaktoren wurden 
daraufhin verglichen. In Zellen mit hoher p110δ Exprimierung, wie z.B. SH-SY5Y, konnten 
wir eine zentrale Rolle dieser Isoform in der Regulierung des Überlebens unter limitierenden 
Zellkultur Bedingungen, sowie für die Wachstumsfaktor-induzierte Proliferation nachweisen. 
Diese Studien haben eine neue Funktion von p110δ in der Regulierung der Proliferation von 
NB Zellen aufgezeigt. Des Weiteren konnten wir darlegen, dass p110α und p110δ nicht-
überlappende Funktionen in diesen Tumorzellen haben. 
 In einem Nebenprojekt sollten die Auswirkungen der Inhibition einzelner PI3K 
Isoformen in GB untersucht werden. Diese Gehirntumoren zeichnen sich durch einen hoch-
invasiven Phänotyp aus und stellen die bösartigste Form von Glioma dar. Obwohl eine 
Vielzahl von Studien aufgezeigt haben, dass der PI3K/Akt Signalweg eine wichtige Rolle in 
der Pathogenese von Gehirntumoren spielt, bleibt der Beitrag der verschiedenen PI3K 
Miglieder weitgehend unklar. In ersten Versuchen konnten wir zeigen, dass einzelne 
Isoformen in unterschiedlichem Ausmass an der Regulierung verschiedenster biologischer 
Vorgänge beteiligt sind. Die Hemmung der Klasse II Isoform PI3KC2β mit einem 
pharmakologischen Inhibitor führte zu einer verminderten Proliferationsrate von GB Zellen 
und ex vivo Kulturen. Des weiteren wurde die Sensitivität der Zellen auf Chemotherapeutika 
(z.B. Doxorubicin) bei gleichzeitiger Behandlung mit dem Inhibitor erhöht. Erste 
Experimente mit Inhibitoren der Klasse IA PI3K zeigten, dass die Hemmung von p110α bei 
gleichzeitiger Stimulation mit Wachstumsfaktoren eine verminderte Aktivierung von Akt und 
S6 Protein zur Folge hat. Zudem wurde ein Einfluss auf Verankerungs-unabhängiges 
Zellwachstum beobachtet. Die verwandte Isoform p110β scheint ebenfalls an der Regulierung 
von Verankerungs-unabhängigem Zellwachstum und Zellmotiliät beteiligt zu sein. Die 
genauen Mechanismen, die zu den beobachteten Unterschieden führen, bleiben jedoch 
weitgehend unklar.  
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Zusammengefasst ermittelt die vorliegende Dissertation die Rolle des PI3K Signalwegs in NB 
und GB. Dabei werden die funktionellen Unterschiede der einzelnen katalytischen PI3K 
Isoformen aufgezeigt, was die weitläufig anerkannte Ansicht bestätigt, dass individuelle 
Mitglieder spezifische, nicht-überlappende Funktionen haben. Die Erkennung der zentralen 
Rolle des PI3K/Akt Signalwegs in der Krebsentstehung hat die PI3K als neue therapeutische 
Zielmoleküle hervorgehoben. Aufgrund der Existenz von acht Isoformen ist ein detailliertes 
Verständnis der individuellen Funktionen unerlässlich, was den Einsatz von Isoform-
spezifischen PI3K in klinischen Studien jedoch verzöget. Nichtsdestotrotz deuten sowohl die 
gewebespezifische Exprimierung dieser Proteine, als auch die Tatsache, dass sie nicht-
überlappende Funktionen haben, darauf hin, dass die PI3K geeignete Zielmoleküle sind und 
dass sich das Warten durchaus lohnen könnte.  
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2 Introduction 
2.1 Neuroblastoma 
2.1.1 Introduction 
NB is a childhood neoplasm arising from neural crest cells. According to the NCI, NB 
accounts for 7-10% of all cancers diagnosed in children younger than 15 years of age. Two thirds 
of all cases present in children under the age of five. Tumors can arise anywhere along the 
sympathetic nervous system, with about half of all cases arising from the adrenal gland and the 
rest deriving from paraspinal sympathetic ganglia. The symptoms experienced at clinical 
presentation are variable and depend on the site of primary tumor origin. According to the NCI, 
approximately 70% of NB patients have metastatic disease at the time of diagnosis. A 
characteristic feature of this malignancy is the variability in clinical phenotype ranging from 
spontaneous regression to rapid tumor progression, ultimately leading to death.  
Based on the observation that young children with localized tumors have a much better 
prognosis, various attempts have been made to screen infants in order to detect those with early 
onset disease. Although population-based screening trials were able to identify a considerable 
number of NB patients, the tumors detected by this method generally had favorable biological 
features and thus represented cases that presumably would have spontaneously regressed (1, 2). 
Therefore, there seems to be no general health benefit from screening newborns for 
neuroblastoma. Modern technologies, such as microarray analysis, have allowed genome-wide 
comparison of tumors of different stages in order to identify gene classifiers that could be useful 
for predicting clinical outcome and understanding the biology of tumor progression (3, 4). 
However, despite recent advances in understanding the biology of neuroblastoma, this childhood 
cancer remains enigmatic.  
The etiology of NB is unclear (5). While most cases arise sporadically, a small fraction (1-
1.5%) shows familial recurrence (6). To date, the gene (or genes) responsible for the 
development of disease have not been identified, due to a lack of familial clustering or the 
identification of informative families. Nevertheless, a number of characteristic genetic 
aberrations with prognostic value have been discovered during the past few decades (7). The 
most important alterations and their association with different patient groups are summarized in 
Table 2 (adapted from (5)) and discussed in more detail below.  
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In order to ensure accurate risk stratification and choice of therapy, precise staging of 
tumors is a prerequisite. In an effort to develop a classification scheme allowing uniform staging, 
the International Neuroblastoma Staging System (INSS) was developed (8, 9). The INSS largely 
depends on precise analysis of tumor location and lymph node involvement during surgery. This 
system has proven very reliable in staging of NB (10) and is currently used in nearly all 
standardized treatment protocols. An overview of stage characteristics is given in Table 1 
(adapted from (9)). 
 
 
Stage Description 
1 Localized tumor with complete gross excision, with or without microscopic residual disease. Ipsilateral lymph nodes negative for tumor microscopically 
2A Localized tumor with incomplete gross excision. Ipsilateral lymph nodes negative for tumor microscopically 
2B Localized tumor with or without complete gross excision. Ipsilateral lymph nodes positive for tumor, contralateral lymph nodes negative 
3 
Unresectable unilateral tumor infiltrating across the midline (defined as the vertebral 
column), with or without lymph node involvement. Or: Localized unilateral tumor with 
contralateral lymph node involvement. Or: Midline tumor with bilateral extension by 
infiltration or by lymph node involvement. 
4 Any tumor with dissemination to distant lymph nodes, bone, bone marrow, liver skin and/or other organs 
4S Localized primary tumor in patients under one year of age with dissemination limited to skin, liver, and/or bone marrow 
 
Table 1 INSS Staging System (adapted from (9)). This staging system relies on exact 
analysis of tumor location and lymph node involvement by the operating surgeon and has 
proven very reliable in NB staging prior to treatment. 
 
 
A striking feature of NB is its ability to spontaneously regress, a phenomenon that was first 
described more than three decades ago (11). This situation is mainly observed in children with 
small localized tumors belonging to the 4S group, and can even include patients presenting with 
metastatic disease. Regression is usually observed in biologically and clinically favorable tumors 
which require minimal therapy (12). Although a number of hypotheses exist to explain this 
phenomenon (13, 14), the underlying mechanisms remain elusive. 
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2.1.2 Genetic Alterations 
Frequently detected chromosomal aberrations in NB include both gains and losses of 
genetic material (15). A number of studies have demonstrated the prognostic value of cellular 
ploidy, particularly in infants under 1 year of age (16-19). To date, the cause(s) of this form of 
genetic instability as well as the implications for disease progression remain unclear. NB 
commonly display allelic loss of heterozygosity (LOH) within specific regions of chromosomes 
1, 2, 3, 11, 12, 13, 14 and 15 (20, 21). Despite relentless efforts to uncover the link between these 
genetic alterations and disease progression, the exact underlying molecular mechanisms have not 
yet been deciphered. Nevertheless, LOH on chromosomes 1 and 11 has prognostic value, as it is 
observed more frequently in intermediate to high risk tumors (22). In addition, other 
chromosomal aberrations including translocations or amplification of genetic material have 
proven useful for risk stratification. The most well-known example is presumably amplification 
of MYCN which is detected in a considerable percentage of advanced stage tumors and is 
associated with an adverse outcome (23, 24).   
 
 
 Low risk Intermediate risk High risk 
Clinical features       
Age < 1 year > 1 year < 1 year > 1 year < 1 year > 1 year 
Stage 1, 2, 4S 1, 2 3, 4S 3,4 3, 4S 2, 3, 4 
Genetic alterations    
Ploidy triploid diploid / tetraploid diploid / tetraploid 
1p loss rare rare frequent 
11q loss rare frequent rare 
17q gain rare frequent frequent 
MYCN normal normal amplified 
Molecular alterations    
TrkA high low low 
TrkB low low high 
TrkC high low low 
Prognosis    
5-year overall survival 95% 50% 25% 
 
Table 2 Risk stratification system for NB patients (adapted from (5)). This table gives an 
overview of some of the most common genetic alterations found in NB. Aside from age and 
stage, the existence of specific chromosomal abnormalities or expression of Trk-family 
members determine the risk group of a child and thus have an influence on the treatment 
regimen selected.  
Introduction - Neuroblastoma 
9 
2.1.2.1 1p LOH 
1p LOH is detected in nearly a third of all NB patients (22, 25). This alteration is 
associated with an unfavorable outcome, regardless of stage and has been shown to correlate 
with MYCN amplification (26). 1p36 deletions were first reported in NB in 1977 (27) and have 
since been the focus of much attention. The recurrent deletion of this region and its association 
with poor prognosis suggest that a putative tumor suppressor resides within this chromosomal 
area. Ideally, precise knowledge of the genes affected by this deletion could provide valuable 
information concerning the pathogenesis of neuroblastoma. Almost two decades ago, the main 
interest was in mapping the exact location of alteration, which has since been identified in the 
distal region of chromosome 1 and has been mapped to 1p36 (28-31). Around the same time, it 
was observed that cell lines and tumors harboring MYCN amplification show larger regions of 
deletion than those without this amplification (32, 33). More recent studies have been aimed at 
shedding some light on the genes located within the area of deletion. Modern screening methods, 
including microarray analysis, have allowed visualization of differentially expressed genes in 
patients harboring 1p LOH versus patients with an intact chromosome 1 (34-37). While some of 
the genes identified have known functions in neural differentiation, signal transduction in neural 
cells or regulation of the cell cycle (34-37), other genes have not yet been characterized. One 
such example is CHD5, which was identified in multiple analyses (38, 39). Using mouse models, 
this gene was recently shown to be a tumor suppressor that controls proliferation, apoptosis and 
senescence via the p19Arf/p53 pathway (40). Of particular interest for the present study is the 
recent finding that the catalytic PI3K isoform p110δ is also among those genes found to be 
differentially expressed (35-37). This is not surprising, given that PIK3CD, the gene encoding 
this protein, lies at 1p36.2. This observation highlights the potential role this protein could play 
in the pathogenesis of neuroblastoma.  
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2.1.2.2 11q LOH 
Nearly two decades ago, an increasing number of studies reported LOH for alleles on 
chromosome 11q (41, 42). The frequency of this genetic aberration is comparable to LOH at 1p 
and is found in nearly a third of the tumors analyzed (22, 41, 42). The prognostic value of 11q 
LOH has been studied extensively, in part because it inversely correlates with MYCN 
amplification (42, 43) and thus could provide a useful marker for aggressive tumors that lack 
MYCN amplification. Indeed, the prognosis for patients with tumors harboring an unbalanced 
deletion of 11q (11q loss with either retention or gain of 11p material) is very poor, and this 
alteration was shown to be an independent marker of decreased event-free and progression-free 
survival (22). As with 1p LOH, the finding that 11q LOH correlates with poor prognosis 
suggests the presence of a putative tumor suppressor gene within the area of deletion. Current 
investigations are aimed at identifying the genes affected by this loss of genetic information (44, 
45). 
2.1.2.3 17 gain 
The most frequent genetic imbalances, seen in roughly half of all primary neuroblastoma, 
affect chromosome 17 (20, 21). The two types of alterations found are (i) whole chromosome 17 
gain, which is seen more frequently in low grade tumors (20) or (ii) segmental gain of the long 
arm, which is observed in high grade tumors (20) and has been shown to predict an adverse 
clinical outcome (46, 47). Partial gain of chromosome 17q is mostly the result of an unbalanced 
translocation between 17q and a number of partners, including chromosomes 1p, 3p and 11q (48-
52). Because this genetic rearrangement is detected so frequently, many attempts have been 
made to map the breakpoint, which has been found to be highly variable (53, 54). The exact 
mechanisms that lead to the adverse outcome in patients with 17q alterations remain yet to be 
unveiled. Recent attempts to identify genes that are overexpressed in tumors harboring 17q 
translocations have identified several potential candidates, including BIRC5 (survivin) (55), 
NME1 (56) and PPM1D (57). Although 17q gain is very strongly linked to both 1p deletion and 
MYCN amplification, it was shown to be a significant predictive factor in cases where neither of 
the latter alterations were detected (47). This finding is of particular interest, as it could facilitate 
the identification of more aggressive tumors in the intermediate risk group, thus leading to a 
more efficient treatment of certain patients.  
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2.1.2.4 MYCN 
Early studies aimed at identifying genes associated with disease progression in NB 
reported the frequent amplification of chromosomal material, manifested as homogeneously 
staining regions (HSR) or double minute (DM) bodies (58-60). A proto-oncogene, termed MYCN 
due to its partial homology to MYC (encoding c-Myc), was found to be located within the 
amplified regions (61, 62). The MYCN gene is located on chromosome 2p and belongs to the 
family of Myc proteins, which function as transcription factors (63). Unlike c-Myc, which is 
ubiquitously expressed in proliferating tissues (64, 65), N-Myc expression seems to be limited to 
neuroectodermic and mesodermic cells, especially at early stages of differentiation (66). MYCN 
has been the focus of much attention, mainly because it was the first oncogene found to be of 
prognostic value for NB patients (23, 24, 67). Amplification of MYCN is detected in nearly a 
third of all primary NB (24) and is strongly associated with advanced stage disease and adverse 
prognosis (23, 67). This is reflected by the observation that over 40% of disseminated NB 
display MYCN amplification, whereas this rate is less than 10% for localized tumors (68). While 
the exact role of N-Myc in NB development remains unclear, it was shown that this protein 
regulates cell proliferation and differentiation (69-71), as well as invasiveness (72) and 
tumorigenesis (73). It was further shown that treatment of NB cells with 13-cis-retinoic acid, a 
vitamin A analogue known to induce neuronal differentiation of NB cells in vitro (74), leads to 
decreased levels of N-Myc (69, 75, 76). Considering the tremendous number of putative Myc 
family gene targets (77), it is not surprising that such a wide variety of cellular processes are 
affected by altered N-Myc expression levels in neuroblastoma. 
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2.1.3 Therapeutic Approaches 
Prior to therapy, NB patients are assigned to different risk groups based on prognostic 
factors such as age at diagnosis, tumor biology and tumor stage (9, 78). While this risk 
stratification system has facilitated the selection of optimal treatment strategies, there is an 
ongoing interest to incorporate newly identified markers with prognostic value in order to further 
refine this classification system (79). 
2.1.3.1 Low Risk Patients 
Low risk patients include those younger than one year of age at the time of diagnosis with 
low grade tumors lacking MYCN amplification (9). According to the NCI, treatment of these 
patients usually involves surgical resection of the tumor with or without subsequent 
chemotherapy such as carboplatin, doxorubicin or etoposide. The outcome for this patient group 
is excellent as reflected by a disease-free survival rate of over 95% following surgery alone (80, 
81). Treatment of patients with 4S tumors is largely dependent on clinical presentation. In some 
cases, children might only require supportive care, although low-dose chemotherapy or radiation 
can become necessary if complications, such as massive liver involvement, occur (12). 
2.1.3.2 Intermediate Risk Patients 
Intermediate risk patients are generally older than one year of age at the time of diagnosis 
and have intermediate or high grade tumors (9). While copy numbers of  MYCN are typically 
normal, other genetic alterations, such as 11q loss or 17q gain are often observed (5). These 
patients usually undergo surgical resection of the tumor, followed by moderate chemotherapy 
(79). The survival rates in this risk group display considerable variation. While patients younger 
than one year of age display rates around 80%, this value ranges from 50% to 70% for older 
children (82, 83). 
2.1.3.3 High Risk Patients 
High risk patients are usually older than one year of age at the time of diagnosis and have 
intermediate or high grade tumors (5, 9). These tumors often harbor MYCN amplification as well 
as a number of other genetic alterations associated with unfavorable outcome (22-25, 47). 
Patients are typically treated with high-dose chemotherapy prior to surgical resection of the 
tumor (79, 84). In addition to myeloablative chemotherapy, whole-body irradiation and 
autologous stem cell transplantation, patients are frequently treated with 13-cis-retinoic acid in 
order to eliminate persistent minimal residual disease (79). Regardless of the extent of tumor 
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excision, patients also undergo radiation therapy. Despite aggressive treatment, the long-term 
survival rate for this patient group remains dismal (84-86). 
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2.2 Glioblastoma  
 
2.2.1 Introduction 
Brain tumors comprise a heterogeneous group of malignancies which pose a continuos 
challenge to clinicians due to their highly invasive nature and the restrictive properties of the 
blood-brain-barrier (87). According to the American Cancer Society, primary malignant 
tumors of the brain or spinal cord account for approximately 1.3% of all cancers in adults and 
are responsible for more than 2% of all cancer deaths in adults and children. Apart from 
primary tumors, a high incidence of secondary tumors can develop in the brain. These tumors 
originate from malignant tumors located elsewhere in the body and reach the brain via the 
bloodstream (88).   
 
 
 
 
 
 
 
 
 
Table 3 Distribution of all primary brain and CNS tumors by histology (adapted from (89)). 
Gliomas account for nearly 40% of all brain tumors. Together, astrocytomas and GBs make 
up the majority of all gliomas, with GBs accounting for over 50% alone. 
 Histology Percentage (%) 
Predominantly benign tumors Meningioma 30.1 
 Nerve sheath 8.0 
 Pituitary 6.3 
Gliomas Glioblastoma  20.3 
 Astrocytoma 9.8 
 Oligodendroglioma 3.7 
 Ependymoma 2.3 
 Embryonal, including Medulloblastoma 1.7 
Other tumors Lymphoma 3.1 
 Craniopharyngioma 0.7 
 All other 13.9 
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2.2.2 Gliomas 
Gliomas are tumors that originate from glial cells, i.e. astrocytes and oligodendrocytes 
(90). According to the Central Brain Tumor Registry of the United States, they account for 
40% of all primary brain and central nervous system (CNS) tumors as illustrated in Table 3 
(89). Together, astrocytomas and GBs make up the majority of all gliomas, with GBs 
accounting for over 50% alone (89). Other glial tumors include oligodendrogliomas, 
ependymomas and mixed gliomas, which consist of both astrocytic and oligodendroglial cells. 
Gliomas can arise in wide areas of the brain and more than half of all tumors originate in the 
frontal, temporal, parietal and occipital lobes (89).  
Based on the World Health Organization (WHO) classification scheme, tumors are 
graded following analysis of nuclear atypia, mitoses, microvascular proliferation and necrosis 
in the most malignant region of the tumor (91). Prognosis for patients with low-grade gliomas 
is much better than for those with high-grade tumors, as illustrated by the 5-Year Survival 
Rates listed in Table 4 (89). However, despite relentless efforts to understand the molecular 
biology of GB, no curative therapy is available to date and treatment remains merely 
palliative (87). 
 
 
 
Table 4 Distribution of all primary brain and CNS gliomas by histology subtype (adapted 
from (89)). GBs account for roughly half of all gliomas and are by far the most aggressive 
subtype, as illustrated by the dismal 5-year survival rate of 3.3%. 
WHO 
Grade Histology Subtype 
Percentage  of Gliomas 
(%) 
5-Year 
Survival Rate 
(%) 
I Pilocytic Astrocytoma 5.7 91.3 
II Oligodendroglioma 9.2 70.5 
 Diffuse Astrocytoma 1.7 46.9 
III Anaplastic Astrocytoma 7.9 29.4 
 Anaplastic Oligodendroglioma 5.1 40.1 
IV Glioblastoma  50.7 3.3 
 Other Gliomas 19.7  
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2.2.2.1 Glioblastoma Multiforme 
According to the WHO classification scheme, the most malignant type of glioma is 
grade IV GB multifome (hereinafter GB). This type of tumor is characterized by a highly 
invasive phenotype, which hinders complete surgical resection (92). Furthermore, grade IV 
tumors display rapid proliferation and are capable of forming new blood vessels in order to 
maintain their growth (93). Although GB can arise in patients of all age groups, the incidence 
is highest in the elderly (89). Primary GBs arise de novo from glial cells, most frequently in 
older patients with no previous history of low grade tumors. The genetic alterations associated 
with primary GBs include 10q LOH, over-expression or mutation of the epidermal growth 
factor receptor (EGFR), p16 deletions and phosphatase and tensin homolog (PTEN) mutations 
(94). Secondary GBs are often seen in younger patients who were previously diagnosed with 
low-grade astrocytomas. These tumors typically display alterations of TP53 and over-
expression of the platelet-derived growth factor receptor α (PDGFRα)  (94). As in most 
cancers, the pathogenesis of primary GB appears to be a multi-step process, involving a 
variety of genetic alterations (88). The distinct events underlying the development of primary 
or secondary GB ultimately lead to a disturbance of cell cycle control and aberrant RTK 
signaling. Therefore, it is not surprising that a vast number of studies have provided evidence 
that the PI3K/Akt pathway plays a crucial role in the pathogenesis of brain tumors (95-97).  
 
2.2.3 Genetic Alterations 
In view of the abundance of genetic alterations detected in GB, the following 
delineation is limited to alterations implicated in aberrant PI3K/Akt signaling.   
2.2.3.1 10q LOH 
Early analyses of chromosomal abnormalities in GB reported that 60% to 80% of all 
primary tumors harbored genetic alterations on chromosome 10 (98-100). The described 
events included both loss of an entire chromosome 10 or partial deletions (101). Although 
PTEN is a known target of deletion, the appearance of specific patterns of chromosomal loss 
suggests the presence of other tumor suppressor genes within chromosome 10 (102). 
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2.2.3.2 PTEN 
Based on the high frequency of chromosomal irregularities involving chromosome 10, it 
was assumed that a putative tumor suppressor gene resided within this area. In 1997, two 
independent groups identified a gene within the region 10q23 (103, 104) which has since been 
shown to encode PTEN, a dual-specificity phosphatase capable of dephosphorylating both 3-
phosphoinositides and tyrosine-phosphorylated proteins (105). This protein mainly acts as a 
PI3K antagonist and is involved in the regulation of many essential cellular functions, such as 
cell cycle progression, cell migration and apoptosis (105). Studies aimed at identifying PTEN 
mutations in GB have reported that 50% to 70% of primary GBs have PTEN deletion, 
mutation or loss of PTEN expression, implicating PTEN as one of the most affected genes in 
this disease (103, 106, 107). Various studies have demonstrated a correlation between loss of 
PTEN and Akt activation (95, 97), confirming that the PI3K/Akt pathway is deregulated in the 
absence of functional PTEN. 
2.2.3.3 EGFR 
More than two decades ago, a large number of studies reported genetic alterations and 
varying expression levels of genes encoding RTKs in glioma cell lines and primary tumors 
(108-112). To date, one of the most intensively studied RTKs is the epidermal growth factor 
receptor (EGFR). Signaling from this RTK has been shown to be disturbed by a number of 
mechanisms. EGFR gene amplification is observed in 30% to 50% of GBs and leads to 
protein over-expression in the majority of cases (108-110). Deletion mutations are also a 
frequent occurrence in GB. The most prominent deletion leads to the generation of a truncated 
receptor (termed EGFRvIII) which displays ligand-independent activation (113, 114). 
Immunohistochemical analysis of a microarray comprising 45 GB cases demonstrated that 
expression of the EGFRvIII mutant is correlated with elevated Akt activation, and therefore 
represents an alternate mechanism of Akt activation in the presence of wild-type PTEN (95). 
Furthermore, aberrant signaling via the EGFR can be attributed to the establishment of 
autocrine growth factor loops, which have been detected in glioma cells (115, 116). In 
summary, a number of mechanisms can lead to deviant pathway activation emerging from the 
EGFR.  
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2.2.3.4 PDGFR 
PDGF plays a crucial role in normal developmental processes of the central nervous 
system (111). Therefore, it is not surprising that deregulated signaling involving this growth 
factor system has been linked to GB progression. Around the same time interest in the EGFR 
was sparked, a number of studies reported the expression of both the PDGFR and its ligand 
(112, 117), suggesting the presence of an autocrine or paracrine signaling loop. With the help 
of specific PDGFR inhibitors, recent studies have confirmed the existence of self-sufficient 
PDGF signaling in GB (118). Although the exact mechanisms remain elusive, it seems that 
amplifications (119) and activating deletions (120) can contribute to aberrant PDGF signaling.  
2.2.3.5 IGF 
Insulin-like growth factor-I and –II (IGF-I and IGF-II) are growth factors that are 
known to stimulate proliferation in several mammalian cell systems (121). IGF-signaling 
involves a complex network of growth factors and receptors as well as IGF binding proteins 
(IGFBP), which can sequester IGFs, thus affecting their half-lives and bioavailability (122). 
Unlike a number of other growth factors, IGFs circulate in the bloodstream and can therefore 
act as endocrine factors (122). Expression of the IGF receptors (IGFR) in human brain tissue 
was identified more than two decades ago (123, 124). This family of growth factors plays an 
important role in the growth and differentiation of the CNS (125, 126) and it is therefore not 
surprising that deregulated IGF signaling has been found to contribute substantially to the 
development of brain tumors (127, 128). Two recent studies have demonstrated that different 
mechanisms of aberrant IGF signaling can lead to activation of the PI3K/Akt pathway in GB. 
In one report it was shown that expression of IGFBP2 plays a key role in activating Akt (129). 
Another study provided evidence that the IGF-II/PI3K signaling axis is involved in autocrine 
signaling, thus promoting the growth of a subclass of highly aggressive gliomas lacking 
EGFR amplification (130). In summary, deregulated IGF signaling plays a crucial role in 
gliomagenesis and has recently been linked to aberrant PI3K/Akt pathway activation (128-
130). 
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2.2.4 Therapeutic Approaches 
To date, no curative therapy is available for GB (87). Nevertheless, a broad spectrum of 
techniques is available to prolong the survival time of patients. Aside from classical 
approaches such as surgical resection (131) and radiotherapy (132), a number of novel, more 
targeted therapeutic strategies have proven beneficial (reviewed in (87)). Frequently, different 
approaches are combined in order to improve therapeutic outcome (reviewed in (133)). Based 
on tumor grade and symptoms experienced by the patient, different treatment strategies are 
available. While surgical removal is recommended for most gliomas, radiotherapy and 
chemotherapy options depend on tumor stage and location (87). 
2.2.4.1 Surgical Resection 
Due to the highly invasive nature of GB cells, complete surgical resection of tumors is 
nearly impossible (92) and adjuvant therapies are indispensable. Nevertheless, surgery 
remains very important in GB therapy (131). Aside from its crucial role for final diagnosis, 
tumor excision helps alleviate symptoms caused by pressure on parts of the brain. 
Furthermore, it has been shown that extensive resection is a good prognostic indicator for GB 
patients (131).  
2.2.4.2 Radiotherapy 
Postoperative radiotherapy (RT) has become an integral part of standard treatment 
based on the observation that it has a beneficial effect on patient survival (132, 134, 135). A 
variety of radiation strategies are available, ranging from whole brain RT to partial RT and 
including different fractionation schemes. A study performed more than two decades ago 
describing the appearance of recurrent tumors within or in close proximity to the original site 
of tumor origin (136) substantiates the preference of partial RT over whole brain RT. Partial 
RT has the advantage of limiting the area of exposure to radiation, thus reducing the 
occurrence of side effects.  
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2.2.4.3 Chemotherapy 
While surgical resection and postoperative RT form integral parts of current GB 
treatment, the role of chemotherapy is controversial. Although the effects of adjuvant 
chemotherapy are very modest and the ability of some agents to cross the blood-brain barrier 
is questionable, meta-analysis of 12 randomized clinical trials confirmed a beneficial effect of 
chemotherapy on patient survival (137). Novel antineoplastic agents, such as Temozolomide, 
have shown remarkable activity against gliomas, are able to cross the blood-brain barrier and 
have limited side effects (138). While the overall effect of chemotherapy is modest in patients 
with high-grade gliomas, a subgroup (mainly including patients with stage III anaplastic 
oligodendrogliomas) shows a significant response to treatment. Comparison of responders 
and non-responders has allowed the identification of molecular predictors of chemosensitivity 
(139). Their feasibility is currently under investigation. The observation that a subgroup of 
patients can indeed benefit from chemotherapy and the availability of novel agents displaying 
acceptable tolerability have increased the importance of chemotherapy in GB management 
(140, 141). 
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2.3 Phosphatidylinositol 3-Kinases 
 
2.3.1 The Family of PI3Ks 
The PI3Ks are a family of evolutionary conserved lipid kinases, which play a crucial 
role in controlling a wide variety of intracellular signaling events. PI3Ks phosphorylate 
phosphatidylinositol (PI) on the D-3 position of the inositol ring, producing distinct second 
messengers such as PI(3)P (PI(3)P), PI(3,4)P2 (PI(3,4)P2) and PI(3,4,5)P3 (PI(3,4,5)P3) (142). 
These second messengers are known to activate a number of proteins involved in complex 
signaling cascades, ultimately resulting in the regulation of cellular responses including 
growth, proliferation, survival and motility (141). A variety of specialized domains have been 
identified that are involved in recruiting these downstream signaling proteins to the membrane 
(143). The family of PI3Ks consists of eight isoforms, which are grouped into three classes, 
based on sequence homology and in vitro substrate specificity (144). To date, it is unclear if 
each isoform targets a specific downstream effector or if a certain degree of redundancy 
exists. An overview of the various isoforms as well as their substrate specificity and tissue 
distribution is given in Figure 1.  
2.3.1.1 Class I 
Class IA includes the three catalytic subunits p110α, p110β, and p110δ (114). This class 
is known to form heterodimeric complexes with a p85 (p85α or p85β), p55 (p55α or p55γ) or 
p50 (p50α) regulatory subunit containing Src-homology 2 (SH2) domains. Sequence 
comparison of the catalytic subunits revealed high homology among the proteins. Class IA 
PI3Ks are important mediators of signal transduction from activated RTK. The regulatory 
subunits are recruited to activated RTKs by means of two SH2 domains, which recognize 
specific phosphotyrosines within the cytoplasmic domain of the receptor (142). While the 
expression of p110α and p110β is ubiquitous, p110δ expression seems to be more tissue 
specific (142, 145). High levels of this isoform have mainly been reported in cells of the 
hematopoeitic system. However, p110δ has also been detected in cells of breast or 
melanocytic origin (145-148).  
Class IB is made up of p110γ and a regulatory subunit p101 (149) or p84 (150). 
Activation of p110γ is controlled by receptors capable of activating heterotrimeric guanine 
nucleotide-binding proteins, termed G protein-coupled receptors (GPCRs) (149). The PI3K 
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p110γ is thought to link GPCR signaling to PI(3,4,5)P3 production, governing cell motility in 
inflammatory cells such as macrophages and to some extent in neutrophils (151). 
2.3.1.2 Class II 
Class II of PI3K comprises the three isoforms PI3KC2α, PI3KC2β and PI3KC2γ which 
differ from class I enzymes in size and substrate specificity in vitro (142, 144). The hallmarks 
of class II family members are a substrate specificity restricted to PI and PI(4)P in vitro, and a 
C-terminal C2 domain. Although the precise cellular function of these enzymes remains 
generally unknown, recent reports have described class II PI3Ks as downstream transducers 
of activated polypeptide growth factor receptors (152, 153) and as regulators of cell migration  
(154, 155).  
2.3.1.3 Class III 
Class III includes the mammalian homolog of the yeast vesicular protein-sorting protein 
Vsp34 (156). The major function of this isoform seems to be in intracellular trafficking events 
(157). More recently, Vsp34 has been found to be an activator of autophagy, contributing to 
early steps of autophagosome formation (158).  
 
 
Figure 1 Overview of PI3K isoforms. The PI3K family consists of eight isoforms, which are 
grouped into three classes, based on sequence homology and in vitro substrate specificity.  
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2.4 Signaling from Activated Receptor Tyrosine Kinases 
 
2.4.1 Activation of Receptor Tyrosine Kinases 
RTKs play an essential role in cellular signaling and are involved in the regulation of 
many normal physiological processes, such as cell proliferation (159) and survival (159) as 
well as cell cycle control, cell adhesion and migration (160). Numerous RTKs have been 
identified and are classified based on ligand preference, induction of biological responses and 
primary structure (161). Their localization in the cellular membrane allows them to translate 
environmental cues, such as peptides, proteins, lipids, or carbohydrates into intracellular 
signals thus determining the biological outcome (161). 
RTKs belong to the family of protein tyrosine kinases, which posses an intrinsic protein 
kinase activity, allowing the transfer of phosphate from adenosine triphosphate (ATP) to 
tyrosine residues of protein substrates (162). Tight control of receptor activity is guaranteed 
by protein-tyrosine phosphatases, by serine/threonine kinases as well as autoregulatory 
mechanisms within the receptors (161, 162). Upon ligand binding, conformational alterations 
are induced, allowing receptor dimerization and, ultimately, autophosphorylation of specific 
tyrosine residues within the cytoplasmic domains (163). Tyrosine autophosphorylation 
stimulates the intrinsic kinase activity of RTKs and leads to the generation of specific 
recruitment sites for important signal transducers (163). Downstream signaling is initiated 
when molecules bearing specialized phosphotyrosine-recognition domains, such as SH2 (164) 
or phosphotyrosine-binding (PTB) (165) domains bind to phosphotyrosine residues within the 
receptor. These signaling molecules are either adaptor proteins that contain additional protein-
protein interaction motifs (e.g. Grb2 or Shc), proteins whose activity is stimulated upon 
association with the receptor (e.g. PI3Ks or PLCγ) or docking proteins, which bear domains 
allowing interaction with the activated receptor, the cellular membrane as well as other 
proteins (e.g insulin receptor substrate (IRS)). The unique combination of proteins recruited to 
the receptor thus determines the specific signaling cascade activated upon ligand binding. 
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2.4.2 PI3K Signaling from Activated Receptor Tyrosine Kinases 
As mentioned above, RTKs undergo autophosphorylation of tyrosine residues within 
the intracellular domain following ligand binding, thus generating docking sites for proteins 
with specific recognition domains. Class IA PI3Ks are important mediators of downstream 
signaling and can be activated by different mechanisms, all involving the association of 
proteins bearing specialized domains with phosphorylated tyrosine residues within RTKs 
(166). Direct interaction with these residues is mediated by SH2 domains of the p85 
regulatory subunit (167), while indirect interaction involves scaffolding proteins and the 
adaptor protein Grb2 or IRS, which can associate with p85 (168). Binding of the regulatory 
subunit to the receptor triggers activation of the catalytic PI3K subunit p110, leading to a 
sharp increase in cellular 3-phosphoinositides. The second messenger PI(3,4,5)P3 is the main 
effector of PI3K signaling and serves as a docking site for proteins bearing a pleckstrin 
homology (PH) domain (169). Two examples of proteins containing a PH domain are 3’-
phosphoinositide-dependent kinase-1 (PDK1) or Akt. Upon binding to PI(3,4)P2 or 
PI(3,4,5)P3, Akt undergoes a conformational change, exposing two amino acids crucial for 
protein activation (170). Thr308 is located within the kinase domain and is phosphorylated by 
PDK1, thus stabilizing the activation loop (171). Since the kinase activity of PDK1 is not 
influenced by its binding to PI(3,4,5)P3, the PH domain seems to mainly ensure the proximity 
of this kinase to its substrate (172). The other amino acid, Ser473, lies within the C-terminal 
domain and requires phosphorylation by a different kinase for full activation of Akt (170). A 
variety of kinases have been suggested to be involved in activating Ser473, such as PDK1 
(173), integrin-linked kinase (174, 175), Akt itself (176) or, more recently, the mammalian 
target of rapamycin (mTOR)-rictor complex 2 (mTORC2) (177). This kinase is most 
frequently referred to as phosphoinositide-dependent kinase-2 (PDK2) (178). Although a 
wide variety of intracellular proteins contain lipid-binding domains, Akt is thought to be the 
main mediator of PI3K signaling due to its crucial role in regulating downstream substrates 
thus controlling essential cellular functions such as apoptosis, cell cycle progression, 
transcription and protein translation (141). Although the complete spectrum of proteins 
involved in PI3K/Akt signaling may not be completely understood, a number of important 
mediators are known, including tuberous sclerosis complex 1 and 2 (TSC1, TSC2), Ras 
homologue enriched in the brain (Rheb), mTOR, 4E-binding protein (4E-BP), ribosomal 
protein S6 kinase (S6K), BAD and glycogen synthase kinase-3 (GSK-3) (142). An overview 
of the pathway is given in Figure 2.  
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While activating signals are crucial to most biological processes, the abrogation of these 
signals is just as important to ensure proper cellular control. The main antagonist of PI3K 
signaling is the phosphatidylinositol 3-phosphatase PTEN. This phosphatase can specifically 
hydrolyze the D3 phosphate, thus controlling the levels of second messengers generated. 
(179, 180). The importance of this protein in ensuring accurate cellular functioning is 
highlighted by the high frequency of PTEN mutations in a number of human cancers, as 
discussed in 2.5.2.1 (103, 104). 
Although PI3K signaling plays an important role in transmitting signals from activated 
RTKs, it is not the only pathway that is activated upon ligand binding. Another key pathway 
involves the mitogen-activated protein kinase (MAPK) cascade (181). All eukaryotic cells 
possess multiple MAPK pathways, which are divided into different groups based on sequence 
similarity (182). Although MAPKs can be activated by a wide variety of stimuli ranging from 
growth factors to cellular stress (183), each family is composed of a set of three evolutionarily 
conserved, sequentially acting kinases: a MAPKK kinase (MAPKKK), a MAPK kinase 
(MAPKK) and a MAPK (182). The cascade comprised of Raf, MEK and extracellular signal-
regulated kinases 1 and 2 (ERK1/ERK2) plays an essential role in relaying signals from 
activated RTKs. Upon ligand binding, this pathway is activated by the GTPase Ras, which 
can bind directly to Raf (184). Activated ERK1 and ERK2 have been shown to phosphorylate 
a variety of substrates including membrane proteins, nuclear substrates, and cytoskeletal 
proteins (185). An overview of the pathways involved in transmitting signals from activated 
RTKs is given in Figure 2. 
As a greater understanding of signaling from activated RTKs arises, it has become 
increasingly clear that these cascades do not form linear pathways, but instead constitute 
complex signaling networks, converging to activate downstream substrates (186) or 
regulating each other’s activity (187). 
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Figure 2 Schematic overview of signaling from activated RTKs. Upon ligand binding, the 
transmembrane receptor is activated by autophosphorylation, creating binding sites for adaptor 
proteins, such as the Src-homology collagen protein (Shc) or growth factor receptor-bound protein 2 
(Grb2). Signals are transduced via the MAPK or the PI3K pathway. Key upstream regulators of 
MAPK signaling include Grb2, Son of Sevenless (SOS), Ras, Raf, MAPK/Erk kinase (MEK), 
extracellular signal-regulated kinase (ERK). Activation of the PI3K pathway is initiated by 
recruitment of the PI3K complex to the phosphorylated receptor through interactions via the 
regulatory subunit p85. Downstream signals are transduced via phosphoinositide-dependent kinase-1 
and -2 (PDK1 and PDK2), protein kinase B/Akt (AKT), forkhead (FKHR), BAD, glycogen synthase 
kinase-3β (GSK3β), tuberous sclerosis complex (TSC1/2), Ras homologue enriched in the brain 
(Rheb), the mTOR-Raptor complex, 4E-binding protein (4E-BP) and ribosomal protein S6 kinase 
(S6K). 
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2.5 Genetic Alterations of PI3K Isoforms and Their Implication in Cancer 
 
2.5.1 Introduction 
Considering the crucial role PI3K/Akt signaling plays in regulating cell survival, it is 
not surprising that genetic alterations leading to increased pathway activation are detected in 
various human malignancies (188-190). In fact, the PI3K/Akt cascade is now known to be one 
of the signaling systems most frequently targeted by mutations or amplifications in human 
cancers (188). This finding has put PI3K/Akt signaling in the spotlight and has led to the 
emergence of a plethora of studies analyzing the mechanisms leading to deregulation of this 
pathway in malignant cells. Unfortunately, the majority of publications focus only on 
PIK3CA, completely disregarding the other PI3K isoforms. An overview of genetic 
alterations pertaining to components of the PI3K pathway in NB and GB is given in Table 5. 
 
2.5.1.1 PIK3CA 
Mutation of PIK3CA  
A landmark study by Samuels et al. performed on a variety of different tumor types 
found that a high percentage of colorectal cancers, GBs, breast and gastric cancers harbored 
mutations in the PIK3CA gene (191). Genetic alterations in this gene were also detected in 
lung cancer, albeit at much lower rates (191). A large number of studies have since reported 
the existence of PIK3CA mutations in a variety of human malignancies (192-194). 
Interestingly, around 80% of the mutations map to one of three known hot spots, which are 
characterized by substitution of a single amino acid: E542K, E545K and H1047R. Studies 
aimed at characterizing these mutants have demonstrated their oncogenic potential (195-197). 
Neuroblastoma To date, a single study has investigated the rate of PIK3CA mutations in 
NB. Two mutations were found in a total of 69 primary tumor samples, indicating that this 
genetic alteration is rare in NB (198). Although the alterations detected did not lie within the 
known hot spots, they were found to be located within the kinase or helical domains, 
implicating a possible increase in p110α activity.  
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Glioblastoma  In GB, the values pertaining to PIK3CA mutations range from 0% (n=70) 
(199) to 27% (n=15) (191). The most consistent values seem to be around 5%, a number 
reported by various groups (200-203). A slightly higher rate of 18% was detected in a panel 
of primary tumors comprising 38 samples (204). The large discrepancies observed among 
these studies can possibly be explained by (i) the samples sizes, which are usually fairly 
small, (ii) by the composition of the samples, which in some cases contain both adult and 
pediatric tumor samples or (iii) the methods of detection, which can display different 
sensitivities. Barring the inconsistent rates of mutation, a common finding is that mutations in 
PIK3CA and PTEN seem to be largely mutually exclusive in GB (200-203). 
 
Amplification of PIK3CA 
Comparatively few studies have been aimed at evaluating the incidence of PIK3CA 
amplifications in human cancer. Nevertheless, amplification seems to play a role in the 
pathogenesis of certain malignancies, such as thyroid, lung or ovarian cancer (205-207) and 
could provide an alternative mechanism of pathway activation in the absence of mutations. 
This idea is substantiated by the observation that amplification of PIK3CA is a rare event in 
breast cancer, where mutation of this gene is one of the most frequent genetic alterations 
detected (208, 209). 
Neuroblastoma Despite the growing interest in linking PIK3CA alterations to the 
pathogenesis of various human cancers, to date, not a single study has assessed the 
amplification rates of this gene in NB. A single research paper evaluating genomic DNA 
alterations in a panel of 42 NB cell lines reported no significant amplification of the PIK3CA 
locus (3q26) (210). Therefore, the contribution of p110α to the development of this pediatric 
cancer remains yet to be investigated. 
Glioblastoma  In GB, numbers concerning PIK3CA amplification rates are as diverse as 
those regarding mutation rates. While most groups have reported the total absence of PIK3CA 
amplification (200, 202, 204, 211), a few studies have demonstrated increased copy numbers 
of this gene (203, 212). However, the relevance of this genetic alteration for gliomagenesis 
remains to be evaluated. 
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2.5.1.2 PIK3CB 
Very little is known about genetic alterations of PIK3CB in human cancer. However, 
despite its chromosomal proximity to PIK3CA, this isoform does not seem to be the target of 
mutational events (191), as illustrated by analysis of a large number of primary tissues and 
cell lines derived from malignant tumors (www.sanger.ac.uk/perl/genetics/CGP/cosmic).  
Neuroblastoma There is currently no data available concerning PIK3CB mutation or 
amplification rates in NB. 
Glioblastoma The only study aimed at investigating PIK3CB mutations in GB reported 
no mutation of this isoform upon sequence analysis of 10 primary tumors (212).  
 
2.5.1.3 PIK3CD 
Although PIK3CD does not seem to be frequently targeted by mutations, as exemplified 
by large-scale mutational analysis (www.sanger.ac.uk/perl/genetics/CGP/cosmic), alterations 
in gene copy numbers and mRNA levels could be involved in the development of certain 
cancers, including NB and GB. 
Neuroblastoma Recent microarray-based studies performed on primary NB samples 
have reported decreased expression of PIK3CD in distinct patient groups, such as those 
harboring 1p LOH (36) or those with unfavorable biology (37). Interestingly, in tumors with 
amplification of MYCN, an important prognostic marker, levels of PIK3CD mRNA were 
found to be decreased (37). Analysis of primary NB samples included in the present thesis 
revealed that elevated mRNA levels of PIK3CD correlate with patient age (<1 year of age). 
Furthermore, mRNA levels were shown to be predictive of protein levels. A single study has 
investigated the mutational status of PIK3CD in NB. This report found that 2/46 primary NB 
samples harbored genetic alterations in the gene encoding p110δ (213). However, the 
biological consequence of these mutations remains to be investigated. 
Glioblastoma A study comprising 103 GB tumor samples found that the mRNA levels 
of PIK3CD were elevated, despite normal copy numbers (211). A much smaller study 
encompassing 10 primary tumor samples subsequently found balanced copy number increases 
in PIK3CD (212). 
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2.5.1.4 PIK3R1/PIK3R2 
Reports on the involvement of the regulatory PI3K subunits in cancer progression are 
quite rare. Nevertheless, it has been shown that some primary human colon and ovarian 
cancers harbor mutations in PIK3R1, producing deletions within the inter-SH2 region, thus 
leading to PI3K activation (212, 214). 
Neuroblastoma To date, no data is available pursuant to PIK3R1 or PIK3R2 mutation or 
amplification rates in NB. However, expression profiling of 68 neuroblastoma samples 
revealed decreased expression of PIK3R1 in stage 4 patients (4). 
Glioblastoma  Analysis of copy numbers and expression levels of PIK3R1 and PIK3R2 
in GB revealed no differences when compared to non-neoplastic human brain tissue (211). A 
study encompassing 30 GB samples detected a deletion mutation in one sample (212). This 
mutation is predicted to give rise to a C-terminal deletion, possibly conferring oncogenic 
potential to the truncated protein (212). 
 
2.5.1.5 PIK3C2A/PIK3C2B 
Despite their established role in transducing signals from activated RTKs, very little is 
known about genetic alterations of the class II isoforms PIK3C2α and PIK3C2β in cancer 
(215). Large-scale mutational analysis revealed that mutations in PIK3C2A  and PIK3C2B are 
nearly absent in most cancers (www.sanger.ac.uk/perl/genetics/CGP/cosmic) (191).  
Neuroblastoma There is currently no data is available regarding genetic alterations of 
PIK3C2A or PIK3C2B in NB. 
Glioblastoma In GB, 6% of tumor samples were found to have amplification of 
PI3KC2B, accompanied by an almost identical rate of mRNA over-expression (211). To date, 
no mutational analysis of class II PI3Ks has been performed in GB.  
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2.5.2 Alterations of Genes Involved in PI3K Signaling 
2.5.2.1 PTEN  
As discussed in chapter 2.2.3.2, PTEN is a firmly established tumor suppressor gene 
frequently involved in deregulated PI3K signaling. Genetic alterations involving this gene are 
implicated in the progression of a variety of human malignancies (105). 
Neuroblastoma Although genetic alterations of PTEN play a key role in the progression 
of various human cancers, detailed analysis of a panel of NB cell lines led to the conclusion 
that disruption of the PTEN gene is not a frequent event in this cancer (216).  
Glioblastoma The observation that 50% to 70% of all primary GBs have PTEN 
deletion, mutation or loss of PTEN expression, implicates PTEN as one of the most affected 
genes in this disease (103, 106, 107). While genetic alterations of PTEN are prevalent in adult 
GB, they are nearly absent in pediatric brain tumors (217), suggesting that the underlying 
mechanisms of tumor development are different in pediatric and adult cancer. 
 
  Neuroblastoma Ref. Glioblastoma  Ref. 
PIK3CA mutation  low rates  (198) varying rates (0%-27%)  
(191, 199-
204) 
 amplification no amplifications  (210) varying rates (0%-50%)  
(200, 202-
204, 211, 
212) 
PIK3CB  no information  no mutations  (212) 
PIK3CD  decreased mRNA levels rare mutations   
(36, 37, 
213) 
increased mRNA 
levels, amplification  (211) 
PIK3R1 
PIK3R2  no information  
mutation of PIK3R1  
no amplification (211, 212) 
PIK3C2A 
PIK3C2B  no information  amplification  (211) 
PTEN  no mutations  (216) frequent genetic alterations (50%-70%)  
(103, 106, 
107) 
 
Table 5 Genetic alterations pertaining to components of the PI3K signaling pathway in NB and GB. 
Most studies are aimed at investigating chromosomal aberrations of PIK3CA, while the mutational 
status of the other isoforms remains largely unknown. 
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2.5.2.2 Receptor Tyrosine Kinases 
RTKs play a crucial role in the biology of many types of human cancer (161). In 
principle, any receptor with tyrosine kinase activity possesses oncogenic potential. Different 
mechanisms can lead to aberrant RTK activation and ultimately to aberrant downstream 
signaling. These alterations are best exemplified by the EGFR, which has been reported to be 
involved in the pathogenesis of a variety of human malignancies, including brain, breast, lung 
and prostate cancer (218). Malignant transformation by oncogenic EGFRs can occur through 
a number of mechanisms including: (i) receptor over-expression (108), (ii) deletion mutations, 
resulting in ligand-independent RTK activation (113, 114), (iii) mutations that affect the 
dimerization properties, leading e.g. to constitutive receptor dimerization (219), (iv) activation 
of autocrine growth factor loops (115, 116) and finally, (v) altered endocytosis of activated 
receptors, leading to prolonged signaling (220). These mechanisms have also been shown to 
be involved in aberrant signaling emanating from other RTKs, including the IGF-IR or the 
PDGFR. Besides providing the cell with a survival advantage, constitutively active RTKs can 
have a chemoprotective effect, making treatment of patients very difficult (221). 
Neuroblastoma In NB, various growth factors have been identified that play a key role 
in tumor cell proliferation as well as in chemoresistance. Early reports demonstrated autocrine 
signaling loops involving IGF-II (222) and stem cell factor (SCF) (223). More recently, it was 
shown that the hepatocyte growth factor (HGF)/c-Met pathway contributes to NB 
invasiveness and malignant transformation (224). The role of EGF and PDGF signaling 
remains ambiguous. More than a decade ago, expression of different PDGFR chains was 
reported in NB cell lines (225). Although it has since been shown that expression of the 
corresponding ligand (PDGF) correlates with advance-stage disease (226), the contribution of 
this growth factor system remains unclear. The role of EGF signaling has not been studied 
extensively, despite a recent report demonstrating that proliferation of human NB is mediated 
by the EGFR (227). By contrast, the Trk-family receptors, which are normally involved in 
regulating basic cellular functions in neuronal cells, have been the focus of much attention in 
NB research (228). Interestingly, over-expression of individual members was found to 
correlate with clinical behavior. While TrkA expression is characteristic of favorable tumors 
(229), TrkB expression is associated with unfavorable, MYCN-amplified NB (230).  
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Glioblastoma The list of growth factors implicated in the biology of malignant glioma 
is long (128). In addition to the intensely studied EGFR and PDGFR (discussed in sections 
2.2.3.3. and 2.2.3.4, respectively) a number of other RTKs are involved in gliomagenesis. 
Expression of IGFs and their corresponding receptors has been extensively studied and has 
led to the proposition of an autocrine signaling loop (123, 231, 232). Furthermore, the HGF/c-
Met pathway has also been found to be deregulated in glioma and appears to be involved in 
the transition from low to high grade tumors (233, 234). Considering the fact that gliomas are 
highly vascularized tumors, it is not surprising that aberrant signaling involving vascular 
endothelial growth factor (VEGF) has been reported in gliomas. In particular, expression of 
this growth factor seems to be involved in the transition to high grade tumors (235, 236).  
In summary, various growth factor systems are implicated in the biology of NB and GB 
and a plethora of studies have substantiated the essential contribution of aberrant RTK 
signaling to tumor development and/or progression in numerous human cancers. 
 
2.5.2.3 Other Signaling Components 
A variety of alterations have been associated with proteins known to contribute 
substantially to PI3K signaling. Mutational analysis has demonstrated that downstream 
molecules, such as Akt and PDK1 are subject to genetic changes in human cancer, albeit at 
low rates (237-241). More recently, extensive gene sequencing analysis has provided a 
plethora of information concerning the mutational status of numerous signaling regulators 
(241-244). Although these studies revealed a number of previously uncharacterized genetic 
alterations, no recurrent novel mutations were detected. In recent years, tissue microarray 
analysis has allowed visualization of pathway activation in a large number of primary tumor 
specimens. This has provided a better understanding of the effects genetic alterations have on 
signaling pathway activation and, in some cases, has revealed novel prognostic markers (245-
247). 
Neuroblastoma To date, little is known about the mutational status of genes involved in 
PI3K signaling in NB. In an attempt to find classifiers predicting patient outcome, large-scale 
cDNA microarray analysis of tumor samples has been performed by a number of groups (3, 
4). The only PI3K pathway component found be relevant for distinguishing between patient 
groups was altered expression of PIK3R1 (4). However, a recent tissue microarray study 
found that phosphorylation of Akt and the ribosomal S6 protein is frequently elevated in 
primary NB (248). Moreover, phosphorylation of Akt was found to correlate with aggressive 
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disease and MYCN amplification and could be shown to be a novel prognostic indicator of 
poor outcome in NB (248). Future studies will hopefully complement these initial findings, 
thus leading to a better understanding of the mechanisms contributing to aberrant PI3K 
signaling in NB. 
Glioblastoma Mutational analysis of genes involved in PI3K signaling revealed 
occasional amplification of the gene encoding Akt, while the FRAP1 gene, which encodes 
mTOR, was not found to be amplified when compared with non-neoplastic brain tissue (211). 
Furthermore, no amplification of the gene encoding S6K was detected in GB (211). A tissue 
microarray study demonstrated that loss of PTEN is highly correlated with Akt activation 
(95). Furthermore, a significant correlation was observed between activation of Akt and 
phosphorylation of downstream signaling molecules, including the S6 protein. A more recent 
study confirmed the correlation between activation of Akt and S6 phosphorylation (96). In 
addition, activation of TSC2, which is thought to be the main downstream mediator of Akt in 
mTOR activation, was found to significantly correlate with Akt activation. A study aimed at 
examining the prognostic value of PI3K pathway activation revealed a significant association 
between PI3K, Akt and S6K phosphorylation and increasing tumor grade, decreased levels of 
apoptosis and adverse clinical outcome (247). In summary, these results highlight the pivotal 
role aberrant PI3K signaling plays in glioma biology.  
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2.5.3 Targeting the PI3K Pathway in Human Cancer 
2.5.3.1 Rationale for Targeting Tyrosine Kinases 
A prominent feature of many tumors involves aberrant signaling involving a number of 
tyrosine kinases. Therefore, the use of small molecule inhibitors targeting the kinase activity 
of these signaling components appears to show much promise. The observation that human 
cancers frequently display over-expression or mutation of tyrosine kinases, including RTKs, 
has led to the development of small molecule inhibitors that specifically target these proteins. 
The most renowned examples of specific tyrosine kinase inhibitors include Gleevec (Imatinib 
mesylate) and Herceptin (Trastuzamab). These two inhibitors exemplify the principal 
mechanisms of targeted therapy: pharmacological inhibition of tyrosine kinase activity and 
blocking of receptor function through monoclonal antibodies.  
Gleevec is a small molecule inhibitor which was identified in a screen aimed at 
identifying compounds capable of inhibiting the ABL kinase (249). This search was initiated 
by the observation that the majority of patients with chronic myelogenous leukemia (CML) 
harbor a characteristic translocation, known as the Philadelphia chromosome, which encodes 
the fusion protein Bcr-Abl (250). Expression of this fusion protein leads to aberrant 
intracellular signaling, ultimately leading to the massive clonal expansion of hematopoeitic 
stem cells (250). Based on the fact that Bcr-Abl can be detected in nearly all patients with 
CML, this oncogene is considered an ideal target. Indeed, Gleevec has shown striking results 
in a high percentage of CML patients (251). This compound has since been integrated into the 
standard treatment regimen of these patients. Due to the inhibitory effect Gleevec has on other 
tyrosine kinases, including the c-kit receptor and the PDGFR, its success is not limited to 
CML. Striking clinical responses have been observed in a subset of gastrointestinal stromal 
tumor patients which display a mutant form of the c-kit receptor, thus expanding the 
repertoire of this compound to other cancers.  
Herceptin is a humanized monoclonal antibody designed to target the Her2 receptor, 
thereby inhibiting growth of Her2-overexpressing cells (252). The rationale for the 
development of this molecule was the observation that Her2 is amplified in roughly a third of 
all patients with invasive breast cancer. This molecular marker is easily detected by 
immunohistochemical analysis, thus allowing selection of patients most likely to respond to 
treatment with Herceptin. Promising clinical responses have allowed the integration of this 
antibody into standard treatment protocols (253).  
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While the effects of Herceptin are of great importance to patients with breast cancer, 
there are limits to the success of antibody-mediated targeting of tyrosine kinases. Numerous 
mechanisms of resistance to therapy are known, including loss of PTEN or the presence of 
circulating truncated forms of Her2, which lead to decreased levels of antibodies available for 
binding of membrane-anchored Her2 (254, 255). Moreover, their range of action is restricted 
to the cell surface and depends on an intact extracellular domain. Small-molecule inhibitors 
can cross the cell membrane, thus allowing access to a larger number of targets. These 
compounds occupy the ATP binding site of catalytic domains, thereby directly preventing 
protein activation. In recent years, a plethora of new kinase inhibitors has evolved from large 
scale screenings with compound libraries (256, 257). While the success story of Gleevec 
raised much hope, it seems to be an exception in the field of drug development. There are 
different reasons for this daunting realization. The majority of human malignancies are 
genetically complex, and it is unlikely that their survival solely depends on the activation of a 
single molecule or RTK (256, 257). Moreover, advanced tumors are genetically unstable, 
allowing the emergence of secondary mutations within the kinase domains of proteins, thus 
potentially leading to acquired resistance to pharmacological inhibitors (258). While targeted 
strategies rarely equal the status of first-line treatment, their use as adjuvants has proven 
efficacious (259). Although it is unlikely that newly developed inhibitors will be able to keep 
pace with Gleevec, the availability of a growing number of compounds could allow 
increasingly targeted therapies, tailored to the molecular fingerprint of individual tumors.  
 
2.5.3.2 Rationale for Targeting the PI3K Pathway 
Considering that certain human cancers, including NB and GB, are found to express a 
variety of different RTKs, it remains unclear whether targeting individual receptors will 
provide a successful therapeutic strategy. An alternative approach would be to identify 
downstream signaling molecules essential for transmitting the proliferative and survival 
message of several different RTKs. The family of PI3K represents such a molecule, in view 
of their crucial role in controlling cell proliferation, survival and motility/metastasis 
downstream of many different RTKs (142, 144, 260). Furthermore, a growing body of 
evidence suggests that that activation of the PI3K/Akt signaling pathway plays an important 
role in conferring broad-spectrum chemoresistance to cancer cells (261-264). Thus, 
concomitant inhibition of the PI3K/Akt pathway could sensitize tumor cells to 
chemotherapeutic agents, enhancing cytotoxicity.  
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Neuroblastoma Activation of the PI3K/Akt pathway has been shown to determine the 
sensitivity of NB cells to chemotherapeutic agents and targeted RTK inhibition in vitro (265-
268). This is exemplified by the finding that the BDNF/TrkB system contributes to 
chemoresistance of NB cells via the PI3K/Akt pathway (266). Further investigations 
identified Akt as a key regulator and showed that pharmacological inhibition of Akt sensitized 
NB cells to chemotherapy (267). Our own work demonstrated that cells with increased 
phosphorylation of Akt and the S6 protein were more resistant to NVP-AEW541, an IGF-IR 
inhibitor (Paper 3.2.2; (265)). Inhibition of Akt activity restored the sensitivity to NVP-
AEW541, corroborating the contribution of Akt to chemoresistance (265). Moreover, it was 
observed that drug-resistant cells secrete factors capable of activating the PI3K/Akt pathway 
in drug-sensitive cells, thus attenuating their response to doxorubicin (268). Although the 
exact mechanism remains elusive, this finding further highlights the importance of the 
PI3K/Akt pathway in regulating the sensitivity of NB cells to chemotherapeutic agents. 
Interestingly, it was recently reported that treatment of MYCN-amplified NB cell lines with 
LY294002, a broad-spectrum PI3K inhibitor, results in decreased N-Myc protein expression 
levels, while mRNA levels remain unaltered (269). A subsequent study showed that treatment 
of NB cells with rapamycin (an mTOR inhibitor) also led to reduced protein expression levels 
of N-Myc (270). These observations illustrate the complexity of PI3K signaling and certainly 
merit further investigation. While a recent analysis showed a correlation between activation of 
Akt and poor prognosis (248), no patient-based study has investigated the relationship 
between PI3K/Akt pathway activation and response to chemotherapeutic agents.  
Glioblastoma  Considering that genetic alterations involving PTEN are frequent events 
in GB and are associated with elevated Akt activity (97), it is not surprising that the PI3K/Akt 
pathway has been found to contribute substantially to chemosensitivity. Loss of PTEN makes 
it particularly difficult to target RTKs, because receptor inhibition becomes uncoupled from 
downstream signaling pathways. In contrast to NB, a number of studies have tried to directly 
assess the link between activated signaling components and the susceptibility to drug-induced 
cell death in primary gliomas, thus allowing the identification of patients most likely to 
respond to treatment. Expression of the EGFR and downstream signaling components was 
analyzed in the context of response to the EGFR inhibitor erlotinib (271). This study found 
that tumors with high EGFR expression and low levels of phosphorylated Akt had a better 
response to erlotinib than those with low EGFR expression and high levels of phosphorylated 
Akt (271). A study published shortly thereafter reported that co-expression of PTEN and the 
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mutated EGFRvIII significantly correlated with responsiveness to EGFR kinase inhibitors 
(272). These and other studies have convincingly demonstrated that deregulation of Akt 
activation contributes to chemoresistance in GB.  
 
 Numerous studies have indicated that Akt is a key mediator of chemosensitivity and 
therefore the feasibility of targeting this molecule has been widely discussed (273, 274). 
However, it is important to keep in mind that Akt represents a crucial nodal point in PI3K 
signaling, integrating extracellular signals and orchestrating subsequent pathway activation. 
Therefore, general inhibition of this molecule could potentially be accompanied by serious 
side effects. Targeting the PI3K family could offer a practicable alternative considering their 
pivotal role in relaying activating signals from a variety of different RTKs. Although the 
classical paradigm suggests p85/p110α as the main PI3K complex involved in signal 
transduction, the existence of eight isoforms leaves room for speculation. In addition, the 
observation that these proteins are expressed in a tissue-specific manner and seem to have 
non-redundant functions makes them interesting targets (188, 189, 275-277). While a vast 
number of compounds has been developed to inhibit various components of the PI3K/Akt 
signaling pathway, the following discussion is limited to PI3K inhibitors. 
 
 LY294002 and Wortmannin 
 The best characterized PI3K inhibitors are LY294002 and Wortmannin, which both 
display activity against multiple PI3Ks. These compounds have been shown to effectively 
inhibit in vitro and in vivo growth of a variety of cancer cells (278-280). Furthermore, when 
used at low doses, they have been shown to enhance the cytotoxic effect of many 
chemotherapeutic agents (261, 281, 282). In addition, a radiosensitizing effect has been 
observed in cells treated either with LY294002 or Wortmannin (283, 284). Despite these 
promising observations, neither compound has entered clinical trials due to high toxicity. 
Nevertheless, they have proved indispensable in dissecting the PI3K/Akt signaling pathway 
and providing insight into the mechanisms leading to chemoresistance.  
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Isoform-Specific PI3K Inhibitors 
In recent years, numerous attempts have been made to develop isoform-specific PI3K 
inhibitors, in order to circumvent the toxic effects of inhibiting multiple PI3K isoforms (188, 
189, 275-277). These efforts have indeed led to the generation of compounds that exhibit 
increased specificity towards individual isoforms. However, their clinical feasibility remains 
to be investigated. In the following paragraphs, inhibitors of the class IA PI3Ks are discussed. 
p110α Screening of a chemical library led to the identification of some of the first 
compounds described to selectively inhibit p110α (285). The systematic search for specific 
PI3K inhibitors triggered the development of numerous other compounds with increased 
specificity towards p110α (286, 287) and led to the discovery of compounds which 
selectively target other catalytic isoforms, including p110β (288). Another p110α inhibitor, 
termed PI-103, was recently identified in a chemical array because of its unique activity 
against genetically diverse glioma cell lines (289). The striking activity of this compound was 
traced to its ability to selectively block not only p110α, but also mTOR (289). This compound 
was found to be well-tolerated in vivo and was highly effective against glioma xenografts 
(289). However, a subsequent study found that PI-103 inhibits all class I catalytic PI3K 
isoforms in the low nanomolar range and is therefore not specific for p110α (290). 
Nevertheless, this molecule revealed the feasibility of targeting multiple molecules within the 
same pathway, thereby inhibiting feedback-mechanisms that can lead to pathway activation as 
observed with the feedback-loop involving mTOR and Akt (291). 
p110β A p110β-specific inhibitor termed TGX-221 was developed in an attempt to 
understand the contribution of p110β to platelet activation (292) and is now commercially 
available.  
p110δ The lack of isoform-specific inhibitors also prompted the development of a 
p110δ inhibitor, termed IC87114. This inhibitor was studied in neutrophils in order to 
investigate the contribution of p110δ to chemotaxis (293). IC87114 has been most extensively 
studied in cells of the hematopoeitic system and was found to affect proliferation and 
chemosensitivity in acute myeloid leukemic cells, while normal hematopoeitic progenitor 
cells remained unaffected (294).  
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The availability of novel small molecule inhibitors of individual PI3K isoforms is very 
exciting. Not only do they provide a valuable tool to elucidate isoform-specific roles in 
cellular responses, but they also raise hope of being able to selectively target this fundamental 
survival pathway in cancer cells with minimal side-effects. Preclinical trials have 
demonstrated that pharmacological inhibition of individual PI3K isoforms results in impaired 
proliferation of a variety of human cancer cells (188, 189, 275-277). While it is highly 
unlikely that the use of PI3K-specific inhibitors as single agents will ever be feasible, their 
combined use with other agents could have a synergistic effect and is thus a promising area of 
application (188, 189, 275-277). However, a number of important issues remain to be 
addressed. Considering the complexity of PI3K signaling, which involves cross-talk with 
other pathways and internal feedback-loops, a detailed understanding of this cascade is an 
absolute must in order to prevent unwanted side-effects. A further challenge arises from the 
high sequence homology within the catalytic domain of class IA PI3Ks, which has impeded 
the development of truly isoform-specific inhibitors. Moreover, a number of allegedly 
specific inhibitors have been found to show activity against PI3K-like kinases, including 
ATM or DNA-PK, thus limiting their use. It must also be kept in mind that the existence of 
isoform-specific PI3K inhibitors will not be beneficial for patients until molecular markers 
and genetic fingerprints have been defined which allow the identification of tumors most 
likely to respond to treatment. A further challenge to targeted therapies is the fact that most 
tumors, especially those in advanced stages, do not rely on the activation of a single pathway 
for survival (259). Working out the ideal combination of proteins to inhibit simultaneously 
should contribute to the success rate of future targeted therapies. Despite these unresolved 
issues, PI3Ks remain interesting molecules for targeted therapeutic approaches (188, 189, 
275-277). Increased activation of this pathway in human cancer is well documented and is 
achieved by a number of genetic alterations which affect the signaling cascade at different 
levels. The existence of eight PI3K isoforms necessitates a detailed understanding of the 
individual functions, thus delaying the race to develop inhibitors for clinical use. 
Nevertheless, the wait could well pay off, considering that these proteins are expressed in a 
tissue-specific manner and seem to have non-redundant functions, thus making them very 
attractive targets 
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3 Results 
 
3.1 Project Descriptions  
 
3.1.1 Targeting the phosphoinositide 3-kinase isoform p110δ impairs growth and 
survival in neuroblastoma cells (Clinical Cancer Research, in press) 
NB is a childhood neoplasm arising from neural crest cells. According to the NCI, NB 
accounts for 7-10% of all cancers diagnosed in children younger than 15 years of age. The 
aim of this study was to assess the contribution of individual PI3K isoforms to the survival of 
NB cells. Cell lines and primary tumors were analyzed for PI3K expression both at the 
mRNA and protein level. Based on the observation that p110δ is highly over-expressed in 
primary tumors, cell lines were generated in which p110α or p110δ were stably 
downregulated using RNA interference (RNAi). Cellular responses, such as basal 
proliferation and PI3K/Akt/mTOR pathway activation upon growth factor stimulation were 
then compared. While downregulation of either p110α or p110δ led to impaired cell growth, 
reduced expression of p110δ had a selective effect on the survival of SH-SY5Y cells. 
Decreased levels of p110δ were found to induce apoptosis and lead to lower expression levels 
of anti-apoptotic Bcl-2 family proteins. SH-SY5Y cells with decreased p110δ levels also 
displayed reduced activation of S6K in response to stimulation with EGF or IGF-I. These 
studies unveiled a novel role for p110δ in the regulation of NB survival, and demonstrated 
that p110α and p110δ have non-redundant functions in these tumor cells.  
 
I performed all experiments aside from Figures 1B (contributed by Alexander Schramm) and 5B 
(performed by Kathrin Doepfner). 
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3.1.2 Protein kinase B modulates the sensitivity of human neuroblastoma cells to 
insulin-like growth factor inhibition (International Journal of Cancer) 
 IGF signaling has been extensively studied in the context of NB proliferation, survival 
and motility and several potential therapeutic approaches involving this growth factor system 
have been reported. This study was aimed at evaluating the potential of a novel IGF-IR 
inhibitor (NVP-AEW541, Novartis) in NB. Moreover, the effect of concomitant inhibition of 
PI3K/Akt signaling components was assessed. NVP-AEW541 was found to inhibit NB cell 
proliferation with varying IC50-values. An inverse correlation was observed between levels of 
phosphorylated Akt and S6 protein and sensitivity to the inhibitor. Treatment of cells with an 
Akt inhibitor restored sensitivity to the IGF-IR inhibitor. In addition to its anti-proliferative 
effects, NVP-AEW541 was found to sensitize NB cells to cisplatin-induced apoptosis. These 
results underscore the importance of IGF signaling in NB and highlight the potential of 
targeting the IGF-IR as a novel therapeutic approach in this pediatric cancer.  
 
 In this manuscript, I performed the experiments with the DNAkt contruct (in Figure 8). 
 
3.1.3 Novel role for insulin as an autocrine growth factor for malignant brain 
tumor cells (Biochemical Journal) 
 Atypical teratoid/rhabdoid tumors (AT/RTs) of the CNS are childhood malignancies 
associated with poor survival rates due to resistance to conventional treatments such as 
chemotherapy. The present study was aimed at gaining a more profound insight into the 
involvement of various RTKs in the survival of AT/RT cells. Both the insulin receptor (IR) 
and the IGF-IR were found to be over-expressed when compared to normal human brain 
tissue. Furthermore, secretion of IGF-I was detected, suggesting the existence of an autocrine 
signaling loop in these cells. IGF-I was shown to effectively activate Akt, indicating a crucial 
involvement of the PI3K/Akt signaling pathway in the signaling loop. By means of isoform-
specific PI3K inhibitors and RNAi, the p110α isoform was identified as a key mediator of 
AT/RT survival and signaling from the activated IGF-IR. Together, these results reveal a 
novel role for autocrine signaling by insulin and the IR in the growth and survival of 
malignant AT/RT cells via the PI3K/Akt pathway.  
  
 My contribution to this manuscript involved ELISA mesurements of IGF-I and IGF-II in samples . 
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3.1.4 Targeting PI3KC2β impairs proliferation and survival in acute myeloid 
leukemia, brain tumors and neuroendocrine tumors (submitted to the British 
Journal of Cancer) 
While much attention has been given to the class I PI3K isoforms, little is known about 
the functions of class II PI3Ks in human cancer. This study was aimed at investigating the 
role of the PI3KC2β isoform in a panel of primary tumors and cell lines. Over-expression of 
PI3KC2β was detected in subsets of tumors and cell lines from acute myeloid leukemia 
(AML), GB, medulloblastoma, NB, and small cell lung cancer (SCLC). Specific 
pharmacological inhibitors of PI3KC2β or small interfering RNA (siRNA) impaired 
proliferation of a panel of cell lines and primary cultures from AML, brain tumors and 
neuroendocrine tumors. Inhibition of PI3KC2β also induced apoptosis in AML and GB cell 
lines and sensitised the cells to chemotherapeutic agents. Furthermore, PI3KC2β inhibition 
impaired the phosphorylation of downstream signalling mediators in AML. Together, these 
data show that PI3KC2β contributes to proliferation and survival in AML, brain tumors and 
neuroendocrine tumors and may represent a novel target in these malignancies.  
 
In this manuscript, I performed all experiments involving NB and GB. Together with Kathrin Doepfner, I 
was responsible for drafting and formatting this manuscript. 
 
3.1.5 Distinct class IA PI3K isoforms regulate glioblastoma cell growth, survival 
and migration (Manuscript in preparation) 
 GB is a common malignant form of brain tumor associated with poor prognosis. The 
PI3K/Akt pathway is frequently activated in GB due to mutations in PTEN, PIK3CA or due to 
mutation or over-expression of RTKs. The expression and functions of the catalytic class IA 
PI3K isoforms were investigated in GB cell lines and ex vivo cultures. Targeting the isoforms 
p110β or p110δ using RNAi or isoform-specific inhibitors did not significantly impair the 
growth of GB cells under normal culture conditions, while inhibition of p110α had a partial 
effect. However, the isoforms p110α and p110β were found to contribute to GB growth under 
anchorage-independent conditions. We further observed a selective role for p110β for 
protecting GB cells from anoikis (detachment-induced apoptosis). In addition, p110β was 
essential for the ability of GB cells to migrate, while p110α and p110δ were dispensable for 
the response. The p110α isoform also appeared to play a role in the chemosensitivity of GB 
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cells towards doxorubicin and cisplatin. Moreover, p110α is essential for RTK coupling to the 
downstream effectors Akt and S6K. Together, these results uncover distinct functions for the 
catalytic class IA PI3K isoforms p110α and p110β in GB cell responses. 
 
 In this manuscript, I performed all experiments except those depicted in Figure 3B-D, which were 
performed by Olivier Pardo. 
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3.2 Manuscripts   
 
3.2.1 Targeting the phosphoinositide 3-kinase isoform p110δ impairs growth and 
survival in neuroblastoma cells 
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3.2.2 Protein kinase B modulates the sensitivity of human neuroblastoma cells to 
insulin-like growth factor inhibition 
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3.2.3 Novel role for insulin as an autocrine growth factor for malignant brain 
tumour cells 
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3.2.4 Targeting PI3KC2β impairs proliferation and survival in acute myeloid 
leukemia, brain tumours and neuroendocrine tumours (Submitted to the 
British Journal of Cancer) 
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3.2.5 Distinct class IA PI3K isoforms regulate glioblastoma cell growth, survival and 
migration  (Manuscript in preparation) 
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4 Conclusions and Future Perspectives 
 
4.1 Conclusions 
 
 The aim of this dissertation was to investigate how the family of PI3Ks contributes to 
the biology of NB and GB. Analysis of primary tumor samples was complemented by 
experiments performed in cell culture, allowing a more detailed investigation of molecular 
pathways. Two important tools used in the described studies included a novel generation of 
pharmacological isoform-specific PI3K inhibitors as well as siRNA- or short hairpin RNA 
(shRNA)-mediated silencing of genes encoding PI3K family members. The data presented 
here supports the widely accepted idea that individual PI3K isoforms contribute differentially 
to cellular responses and provides further insight into the importance of this pathway in the 
regulation of a variety of processes, ranging from proliferation to migration. 
 The main focus was on PI3K/Akt signaling in NB, a pediatric cancer which derives 
from precursor cells of the neural crest (68). This pathway has been shown to be crucial for 
the proper regulation of cellular responses in NB. It is activated in response to growth factor 
stimulation (295) and contributes to chemosensitivity (266). Furthermore, a recent study 
demonstrated a correlation between activation of Akt and poor prognosis in NB patients 
(248). While mutation of PIK3CA and loss of PTEN are frequently detected in various human 
cancers, these genetic alterations do not seem to be the main contributors to aberrant 
PI3K/Akt signaling in NB (198, 216). Therefore, the mechanisms leading to pathway 
activation remain to be elucidated. We could show for the first time that the class IA PI3K 
isoform p110δ plays an important role in NB growth and survival. This isoform was found to 
be over-expressed both at the mRNA and protein level in a subset of primary tumors and cell 
lines. Interestingly, increased expression of p85α/p110δ was mainly detected in children 
under the age of one and was found to inversely correlate with MYCN amplification. 
Considering that PIK3CD lies at 1p36.2, it is not surprising that expression of this gene was 
significantly lower in NB samples with 1p36 LOH (36). It was recently shown that decreased 
expression of PIK3CD correlates with poor clinical outcome (37). Moreover, it was observed 
that 1p36 LOH is associated with MYCN amplification (22). Therefore, it is conceivable that 
reduced expression of PIK3CD correlates with adverse outcome due to its association with 
numerous markers of poor clinical prognosis, including age at diagnosis (>1 year), 1p36 LOH 
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or MYCN amplification. An interesting observation is the inverse correlation between 
PIK3CD expression and MYCN amplification. A number of recent studies have reported 
interactions between the PI3K/Akt pathway and Myc-family proteins. It was shown that c-
Myc expression had a negative impact on both basal and growth factor-induced activation of 
PI3K/Akt signaling (296). Moreover, it was observed that treatment of MYCN-amplified NB 
cell lines with LY294002 (a broad-spectrum PI3K inhibitor) resulted in decreased N-Myc 
protein levels, while mRNA levels remain unaltered (269). A further study showed that 
treatment of NB cells with rapamycin (an mTOR inhibitor) led to reduced protein expression 
levels of N-Myc (Oncogene, in press). It is therefore conceivable that MYCN-amplified NB 
display reduced PIK3CD expression due to one of the following mechanisms: (i) 1p36 LOH, 
(ii) a direct negative effect of MYCN amplification on PIK3CD expression or (iii) because 
they are less dependent on p85α/p110δ signaling. Interestingly, a recent study suggested that 
expression of PIK3CD is regulated by an epigenetic mechanism, and put PIK3CD forward as 
one of the most attractive genes for further studies of NB development and progression (213). 
 Of the three class IA PI3K isoforms, p110δ has been found to show the most tissue-
specific expression pattern in normal tissues. Expression of p110δ is predominantly limited to 
cells of the hematopoeitic system and it is therefore not surprising that increased expression 
has been observed in blast cells of AML patients (297). However, high levels of p110δ have 
also been detected in other human cancer cell lines (148, 298), indicating that aberrant 
expression of this isoform may contribute to the malignant properties of cancer cells. In 
support of this notion, the ability of p110δ to induce the transformation of chicken fibroblasts 
was recently demonstrated (299). Moreover, this isoform has been shown to contribute to 
migration in breast cancer cell lines (148) and was found to play a major role in regulating 
cell proliferation, chemoresistance and activation of Akt in AML cells (294, 297). The 
observation that p110δ is over-expressed in a subgroup of NB patients and contributes to the 
survival and proliferation of these cells is therefore a novel finding. We could further show 
that the class IA PI3K isoforms p110α and p110δ do not have overlapping functions in NB 
cell responses. In SH-SY5Y cells, which express high levels of both isoforms, p110δ 
appeared to play a major role in controlling cell growth and survival under limiting growth 
conditions via the mTOR/S6K pathway. In contrast, in LA-N-1 cells which express only very 
low levels of p110δ, downregulation of p110α had a more prominent effect on cell growth 
and pathway activation. Interestingly, downregulation of p110α or p110δ did not affect Akt 
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activation in response to stimulation with EGF or IGF-I, while mTOR/S6K signaling was 
impaired. This finding suggests that activation of Akt and mTOR/S6K have different 
sensitivities to downregulation of class IA PI3Ks. Furthermore, it is conceivable that other 
PI3K family members can compensate for p110α or p110δ in growth factor-stimulated Akt 
activation (298). In addition, we found decreased levels of the anti-apoptotic Bcl-2 protein in 
SH-SY5Y cells with low levels of p110δ. Based on the observation that Bcl-2 levels were 
elevated in SH-SY5Y cells maintained in high serum conditions, it can be assumed that 
growth factors present in the serum contribute to the regulation of Bcl-2 family member 
expression in these cells. Indeed, it has been shown that IGF-I, which is present in FCS, is 
involved in regulating levels of Bcl-2 (300). In view of the fact that p110δ contributes to IGF-
I signaling in NB cells and that downregulation of p110α had a less pronounced effect on 
proliferation under low serum conditions, it can thus be postulated that p110δ is selectively 
involved in regulating the levels of Bcl-2 family members. However, further studies are 
necessary to validate this hypothesis. From a clinical point of view, these findings indicate 
that the class IA PI3K isoform p110δ may play a role in the development of NB in very young 
patients (<1 year) or in a subset of tumors which do not harbor 1p36 LOH and/or MYCN 
amplification. From a mechanistic point of view, the results presented here are consistent with 
the idea that individual PI3K family members contribute differentially to biological responses 
and thus have non-redundant functions. 
 
Another project aimed at elucidating the role of PI3K family members in GB also 
revealed specific roles for individual isoforms. A variety of biological responses were 
evaluated following treatment of cells with pharmacological isoform-specific PI3K inhibitors 
or upon downregulation of individual isoforms with siRNA. In addition to human cell lines, 
primary human ex vivo GB cultures were analyzed, thus providing a more detailed insight into 
the underlying mechanisms of GB biology. Our preliminary findings suggest that the class IA 
PI3K isoforms p110α and p110β are involved in regulating various biological processes 
crucial for GB survival. Treatment of T98G or U251 cells with an inhibitor of p110α led to 
decreased basal activation of Akt and S6K. This finding is in line with a report involving the 
dual p110α/mTOR inhibitor PI-103, where a dose-dependent abrogation of basal Akt 
activation was observed in glioma cells (289). However, a subsequent report demonstrated 
that PI-103 also has comparable activity against the other class I catalytic PI3K isoforms 
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(290), thus explaining the efficient inhibitory effect of this compound on basal 
phosphorylation of Akt. Nevertheless, these results show that targeted inhibition of PI3Ks can 
abrogate constitutive PI3K/Akt pathway activation. This is of particular interest, considering 
that genetic alterations involving PTEN are frequent events in GB and are associated with 
elevated Akt activity (97). Moreover, basal PI3K/Akt pathway activation has been shown to 
modulate the response to chemotherapeutic agents, such as EGFR inhibitors (271, 272). PI-
103 also showed very promising results in vivo (289). In xenograft models, mice treated with 
the compound showed markedly reduced tumor size compared to control animals, while no 
signs of toxicity were observed (289). Analysis of tumor tissue from treated animals revealed 
decreased levels of phosphorylated Akt and S6 protein, thus confirming the results obtained in 
vitro (289). Our further studies showed that p110α has an influence on the ability of GB cells 
to initiate PI3K pathway activation in response to growth factor stimulation. This is in line 
with the finding that inhibition of p110α has a negative effect on Akt activation. Interestingly, 
we could also show that co-treatment of GB cell lines and ex vivo cultures with a p110α 
inhibitor sensitized cells to treatment with chemotherapeutic agents. Similar findings have 
been reported upon co-treatment of cancer cells with LY294002 or Wortmannin (261, 281, 
282). In additional studies, we found that p110β seems to contribute specifically to the 
regulation of cell motility and anchorage-independent growth. Interestingly, a recent study 
also reported a specific effect of the p110β inhibitor TGX-221 on anchorage-independent 
growth in chicken embryo fibroblasts (301). This is consistent with an earlier report, in which 
it was shown that a constitutively active p110β construct induced colony formation in human 
mammary epithelial cells plated in soft agar (302). We plan to further analyze the mechanisms 
underlying these observations. 
 
Additional studies aimed at assessing the role of the less investigated class II isoform 
PI3KC2β revealed that this family member contributes to the regulation of various biological 
responses in NB and GB. Treatment of NB and GB cell lines with increasing concentrations 
of a pharmacological inhibitor of PI3KC2β (PI701) led to a dose-dependent inhibition of 
proliferation with IC50 values in the low micromolar range. Expression analysis revealed 
increased levels of this isoform in a subset of NB cell lines as well as in NB patients under the 
age of one, when compared to normal adrenal gland. In GB, subsets of cell lines and ex vivo 
cultures also displayed increased expression of PI3KC2β when compared to normal human 
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brain or cerebellum tissue. These findings are in line with previous reports where over-
expression of this isoform was detected in a subset of tumors and cell lines from AML, GB 
and SCLC (154, 202, 298). Co-treatment of GB cell lines and ex vivo cultures with PI701 
sensitized cells to Doxorubicin and led to increased cleavage of caspase 3 when compared to 
single-agent treatment. Additional studies in other cancer cells including medulloblastoma, 
AML and SCLC confirmed the contribution of PI3KC2β to cellular responses, such as basal 
proliferation, chemosensitivity or migration. Together, our studies showed that PI3KC2β is 
over-expressed in a broad spectrum of human cancer cells and could prove to be an attractive 
target for future cancer treatment, considering that pharmacological inhibition of this isoform 
not only reduced basal cell proliferation but also had an effect on chemosensitivity and 
cellular migration. 
 
 The PI3K pathway is frequently affected by a variety of genetic alterations (188) 
ranging from loss of tumor suppressor function (105) to point mutation or amplification of 
signaling molecules (191, 194, 208, 211, 215, 301). A number of these chromosomal 
abnormalities have been shown to contribute to aberrant pathway activation (97) or to confer 
oncogenic potential to the affected proteins (196, 240, 299). Reports concerning the patterns 
of these alterations are conflicting. While mutations in PIK3CA and PTEN seem to be 
mutually exclusive in GB (200-203), gastric carcinoma (303) and large B-cell lymphoma 
(304), the co-existence of PIK3CA/PTEN mutations has been reported in endometrial 
carcinoma (305) and breast cancer (306). Interestingly, some genes seem to be targeted by 
multiple mechanisms, such as PIK3CA, which encodes the catalytic class IA PI3K p110α. A 
number of studies have reported point mutations in PIK3CA in different human cancers (192-
194), which have been shown to have oncogenic potential in vitro (195-197). Amplification 
of PIK3CA has also been detected in numerous human malignancies (205-207) and could 
represent an alternative mechanism of pathway activation in the absence of mutations. This 
idea is substantiated by the observation that amplification of PIK3CA is a rare event in breast 
cancer, where mutation of this gene is one of the most frequent genetic alterations detected 
(208, 209). Although is well established that mutation of PIK3CA leads to activation of Akt in 
vitro (195, 196, 307) and it has been shown that tumor samples harboring PIK3CA mutations 
frequently display elevated levels of phosphorylated Akt (209, 308), the role of gene 
amplification is less clear. In vitro studies have demonstrated that over-expression of wild-
type p110α is not sufficient to induce PI3K/Akt pathway activation or oncogenic 
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transformation (299). Analysis of primary tumor samples with PIK3CA amplification has 
demonstrated that this genetic alteration correlates with increased Akt activation in some 
cancers (205, 309, 310), while an effect on downstream signaling is not apparent in other 
cancers (311). Interestingly, over-expression of p110δ was found to lead to increased 
activation of the PI3K/Akt pathway under serum starved conditions and to induce cellular 
transformation in chicken embryo fibroblasts (299, 301). The observed effects were 
comparable to those exerted by the H1047R mutant of p110α (299), demonstrating that over-
expression of p110δ could potentially contribute to the tumorigenic properties of cancer cells. 
The effect of p110δ on Akt/mTOR/S6K pathway activation was also observed in our studies 
involving NB (Paper 3.2.1), where shRNA-mediated downregulation of this isoform led to 
decreased levels of basal S6 protein phosphorylation, as well as impaired pathway activation 
upon stimulation with EGF or IGF-I. The effects were comparable with those observed upon 
downregulation of p110α, indicating that p110δ contributes substantially to 
PI3K/Akt/mTOR/S6K pathway activation in NB cells. Considering that components of this 
pathway are subject both to genetic mutation and amplification, it remains to be investigated 
which alteration represents a more beneficial target. Both of these chromosomal aberrations 
can lead to increased sensitivity to targeted therapies, as exemplified by the EGFR. Over-
expression of the EGFR has been shown to correlate with increased sensitivity to EGFR 
inhibitors in certain cancers (271, 312). In addition, expression of the truncated form 
EGFRvIII has been found to predict sensitivity to EGFR inhibitors (272, 313). As with the 
EGFR, it could well be that both over-expressed and mutated p110α render a cancer cell more 
susceptible to targeted therapies. In this case, a detailed analysis of tumor samples will be 
crucial to identify patients most likely to benefit from specific PI3K inhibition. 
  
 Childhood and adult cancers differ in their pathogenesis. Cancer is thought to be a 
multi-step process ultimately leading to the progressive transformation of normal human cells 
(314). Numerous environmental factors are known to induce genetic alterations, such as 
exposure to UV irradiation, tobacco carcinogens or even chronic infections by the hepatitis B 
virus (315). It is therefore not surprising that the cancer incidence in a population increases 
with age (314). However, it can be assumed that the majority of these environmental 
influences are not involved in the development of pediatric cancers. In view of the fact that 
only 1-10% of all childhood malignancies arise from a predisposition (316), the events 
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leading to malignant transformation of pediatric cells remain largely unclear. While a number 
of mechanisms can contribute to the tumorigenic properties of cells in adults, only a few of 
these alterations have been detected in pediatric cancers (317). These include increased gene 
expression, fusion events leading to the generation of chimeric transcription factors or 
proteins with altered kinase activity as well as deletion of tumor suppressor genes (317). 
Indeed, comparison of the mechanisms underlying glioma formation in adults and children 
has revealed that some of the most prominent alterations found in adult gliomas, such as loss 
or mutation of PTEN or EGFR amplification are not detected in pediatric tumors (217, 318). 
 In GB, components of the PI3K pathway are affected by both amplification and 
mutation (discussed in Chapter 2.5). In NB, characteristic chromosomal abnormalities of 
genes encoding PI3K signaling proteins, such as mutation/amplification of PIK3CA or loss of 
PTEN function, are largely absent (198, 210, 216). Nevertheless, basal activation of Akt is 
detected in NB samples and has been shown to predict poor clinical outcome (248). Upon 
comparison of the alterations affecting genes involved in PI3K signaling in GB and NB, it 
becomes increasingly clear that despite many differences, aberrant PI3K/Akt pathway 
activation is a common feature in these human malignancies and contributes substantially to 
cellular responses such as proliferation or chemosensitivity (96, 247, 248, 266, 271). Along 
with numerous other studies reporting aberrant PI3K/Akt pathway signaling in a variety of 
human cancers (95, 195, 205, 239, 297, 319), the central role of this pathway in tumorigenesis 
is evident. 
 
 In summary, this thesis provides an extensive overview of the role of PI3K signaling in 
NB and in GB. It highlights the functional differences of individual catalytic PI3K isoforms, 
thus confirming the idea that the members of this family of proteins can have specific and 
non-overlapping functions in cellular responses. In particular, we could show a novel role for 
the class IA PI3K isoform p110δ in regulating NB cell growth and survival. Our studies in GB 
revealed that the class IA PI3K isoform p110α contributes to basal and growth factor-induced 
PI3K/Akt pathway activation, while p110β seems to be involved in regulating anchorage-
independent growth and cellular motility. Finally, the class II PI3K isoform PI3KC2β was 
found to play a crucial role in modulating the sensitivity of GB cells to chemotherapeutic 
agents. The involvement of PI3K/Akt signaling in human malignancies has sparked interest in 
targeting PI3Ks as a novel therapeutic approach (188, 189, 275-277). Their tissue-specific 
distribution and non-redundant contributions to cellular responses make them particularly 
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attractive targets. While the use of small molecule PI3K inhibitors as first-line treatment is 
presumably not feasible, their application in combination with other agents, such as 
chemotherapeutics, could very well be beneficial for patients. Moreover, selective targeting of 
individual isoforms could circumvent the toxicity observed with broad-spectrum PI3K 
inhibitors, such as LY294002 or Wortmannin (277). A better understanding of the unique 
roles individual PI3Ks play in biological responses along with a new generation of isoform-
specific PI3K inhibitors will hopefully allow the implementation of preclinical studies in 
clinical trials within the near future. 
 
4.2 Future Perspectives 
 
In recent years, there has been a growing interest in developing more specific 
therapeutic agents to combat cancer cells. New technologies, such as microarray analysis, 
have allowed large-scale comparison of the molecular fingerprints of different cancers, 
thereby generating huge amounts of information. One of the greatest challenges for the near 
future will be to critically review and validate the obtained results, in order to identify 
proteins that can be used as molecular markers and are realistic targets for inhibition by 
pharmacological compounds. A further challenge is posed by the development of truly 
specific kinase inhibitors, due to high sequence homology among members of certain protein 
families, such as the catalytic class IA PI3Ks. Moreover, a detailed understanding of the 
inhibitory profile of novel compounds against other kinases will be indispensable to allow the 
use in clinical trials. 
 
 A number of groups have performed microarray analysis of NB tumors and cell lines in 
an attempt to gain a more detailed understanding of the molecular differences among patient 
groups. Interestingly, various independent screens have reported the differential expression of 
PIK3CD, the gene encoding the class IA PI3K isoform p110δ, while the expression levels of 
other catalytic PI3K isoforms did not appear to differ in subsets of tumors. While this finding 
is certainly of great interest, a large amount of work remains to be done. We could show for 
the first time that this isoform plays a crucial role in regulating NB cell growth and survival 
through the mTOR/S6K pathway. However, the exact mechanism remains to be elucidated. Is 
there a direct link between p110δ and mTOR? How are the levels of phosphorylated Akt in 
response to growth factor stimulation maintained in the absence of p110α or p110δ? How is 
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p110δ involved in regulating the levels of the Bcl-2 family of proteins? It would certainly also 
be interesting to analyze the activation status of the mTOR/S6K pathway in primary tumors 
by means of a tissue microarray and see if there is a correlation with p110δ expression levels. 
Furthermore, it remains to be determined if a p110δ-specific pharmacological inhibitor would 
show the same effects observed in the cells stably expressing decreased levels of p110δ.  
 
 Our observations concerning the differential contribution of p110α, p110β and 
PI3KC2β to numerous biological responses in GB are interesting and support the idea that the 
various PI3K isoforms have non-overlapping functions. However, considering that most of 
the studies were performed with isoform-specific pharmacological inhibitors, it is absolutely 
necessary to validate these results with experiments based on downregulation of the different 
isoforms by means of siRNA. If the results can be confirmed, there are certainly a number of 
aspects that would be interesting to further investigate. Is the effect of p110α-inhibition on 
growth factor-induced PI3K/Akt activation reflected in a decreased proliferative response? 
How do p110α and PI3KC2β contribute to the observed effects on chemosensitivity? And 
further, how is p110β involved in regulating anchorage-independent growth and cellular 
motility?  
 
 In summary, there are quite a few issues that could be addressed based on the results 
presented in this thesis. While each new finding will certainly raise a number of new 
questions, the picture of PI3K signaling will hopefully become more complete in the near 
future, thus allowing the identification of promising new therapeutic targets for further 
investigation. 
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5.2 Recent Patents of Gene Sequences Relative to the Phosphatidylinositol 3-
kinase / Akt Pathway and their Relevance to Drug Discovery 
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5.3 Targeting receptor tyrosine kinase signaling in acute myeloid leukemia 
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